{"kOdHgcAAAAAJ": [["Marc Israel", 2020, "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol"], ["Helen M Colhoun", 2020, "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol"], ["Dirk M\u00fcller-Wieland", 2020, "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol"], ["Catherine Domenger", 2020, "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol"], ["Rita Samuel", 2020, "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol"], ["Stefano Del Prato", 2020, "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol"], ["Lawrence A Leiter", 2020, "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol"], ["Kausik K Ray", 2020, "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol"], ["Bertrand Cariou", 2020, "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol"], ["Alexia Letierce", 2020, "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol"], ["Francisco J Tinahones", 2020, "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol"], ["William Stager", 2020, "Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data"], ["Jaime A Davidson", 2020, "Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data"], ["Sachin Paranjape", 2020, "Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data"], ["Rachele Berria", 2020, "Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data"], ["Deepak L Bhatt", 2020, "The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients \u2026"], ["Hwee Teoh", 2020, "The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients \u2026"], ["David ZI Cherney", 2020, "The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients \u2026"], ["Cyril David Mazer", 2020, "The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients \u2026"], ["Bernard Zinman", 2020, "The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients \u2026"], ["Richard E Gilbert", 2020, "The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients \u2026"], ["Erika Opingari", 2020, "The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients \u2026"], ["Subodh Verma", 2020, "The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients \u2026"], ["Fei Zuo", 2020, "The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients \u2026"], ["Yi Pan", 2020, "The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients \u2026"], ["Andrew T Yan", 2020, "The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients \u2026"], ["Kim A Connelly", 2020, "The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients \u2026"], ["Adrian Quan", 2020, "The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients \u2026"], ["Fouzia Laghrissi-Thode", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["Prediman K Shah", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["John JV McMurray", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["Philip J Barter", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["Eran Leitersdorf", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["Gregory G Schwartz", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["David Preiss", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["Anders G Olsson", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["John Kittelson", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["Christie M Ballantyne", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["Jean-Claude Tardif", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["David Kallend", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["Donald M Black", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["Stephen J Nicholls", 2020, "Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease"], ["National Center for Health Statistics", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Jane F Ferguson", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["PM Ho", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["EC Aneni", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Luc Djousse", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Michael E Mussolino", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["J Mai", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["GF Tomaselli", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["K Bhalla", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["HM Gonz\u00e1lez", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["MM Graham", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["PL Lutsey", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["OJ Heinonen", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["L Roberson", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["G Birbeck", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["CM Shay", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["and Stroke Council", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["David L Tirschwell", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["T Laitinen", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Emily B Schroeder", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Amanda Marma Perak", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["US Census Populations With Bridged Race Categories", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Y Li", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Clifton W Callaway", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Matthew Shane Loop", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["US Census Bureau population estimates: historical data: 2000s", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Pamela L Lutsey", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Emelia J Benjamin", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["L Zhao", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Y Wu", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Alexander R Chang", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Alvaro Alonso", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["JE Freedman", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["G Nichol", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Ten\u00e9 T Lewis", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["HM Rosenberg", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["R Hernandez", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["T Feldman", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["TT Laitinen", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["A Spahillari", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["DK Moser", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Uchechukwu KA Sampson", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["DM Lloyd-Jones", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Susan Cheng", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["ES Spatz", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Alanna M Chamberlain", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Centers for Disease Control and Prevention", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["D Mozaffarian", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["S Davis", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["R Murillo", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Andrew E Moran", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["HS Gooding", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["JG Terry", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["CJ Rodr\u00edguez", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["RL Sacco", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["S Das", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Council on Peripheral Vascular Disease", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["R Kociol", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["M Aziz", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Judith H Lichtman", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["M Oikonen", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["SR Daniels", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["A Younus", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["LJ Appel", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["R Foraker", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["S Talegawkar", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Daniel T Lackland", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["O Ogunmoroti", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Salim S Virani", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Z Nie", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["S Yu", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["FA Masoudi", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["M Guo", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["DC Goff Jr", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Seth S Martin", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Sadiya S Khan", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["S de Ferranti", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["O Hartiala", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["World Health Organization", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Connie W Tsao", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["L Taittonen", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Kunihiro Matsushita", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Myriam Fornage", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Wayne D Rosamond", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Nicole L Spartano", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Svati H Shah", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["American Heart Association Council on Quality of Care and Outcomes Research", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["GA Talavera", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["April P Carson", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["H Yang", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["X Gao", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Y Chen", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["KP Alexander", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Francesca N Delling", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["RN Anderson", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Z Li", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["C Atkinson", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["AR Folsom", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["K Greenlund", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["X Guo", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["JS Viikari", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["CJ Murray", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["JS Rumsfeld", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["American Heart Association", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["D Labarthe", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Y Hong", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["MS Slaughter", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Y Chang", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["JR Kizer", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Mitchell SV Elkind", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["American Heart Association Strategic Planning Task Force and Statistics Committee", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Chris T Longenecker", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Marcio S Bittencourt", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Gary M Satou", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Lisa B VanWagner", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["S Daniels", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["VL Roger", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["H Yatsuya", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Council on Cardiovascular and Stroke Nursing", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["KG Smolderen", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Kristen L Knutson", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["G Heiss", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Christina M Shay", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["JA Nettleton", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["A Correa", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["L Zhou", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["J Lima", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["SS Ali", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Tak W Kwan", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["K Pahkala", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["JJ Carr", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["M Cushman", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["W Tarraf", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["R Malik", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Council on Epidemiology and Prevention", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["L Guo", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Y Ou", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["LC Gallo", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["CU Osondu", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["ARIC Study Investigators", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["L Van Horn", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Y Sun", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["MA Sabin", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["CG Magnussen", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Andrew Stokes", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["G Sun", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Gregory A Roth", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["WD Rosamond", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Brett M Kissela", 2020, "Explaining the slowdown in medical spending growth among the elderly, 1999-2012."], ["Taufiq Salahuddin", 2020, "Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial"], ["David A Latter", 2020, "A LEADER in the management of type 2 diabetes and cardiorenal disease."], ["Ingrid AM Gause\u2010Nilsson", 2020, "Cardiovascular and renal benefits of dapagliflozin in patients with short and long\u2010standing type 2 diabetes: analyses from the DECLARE\u2010TIMI 58 trial"], ["Marc S Sabatine", 2020, "Cardiovascular and renal benefits of dapagliflozin in patients with short and long\u2010standing type 2 diabetes: analyses from the DECLARE\u2010TIMI 58 trial"], ["Avivit Cahn", 2020, "Cardiovascular and renal benefits of dapagliflozin in patients with short and long\u2010standing type 2 diabetes: analyses from the DECLARE\u2010TIMI 58 trial"], ["Aliza Rozenberg", 2020, "Cardiovascular and renal benefits of dapagliflozin in patients with short and long\u2010standing type 2 diabetes: analyses from the DECLARE\u2010TIMI 58 trial"], ["Ofri Mosenzon", 2020, "Cardiovascular and renal benefits of dapagliflozin in patients with short and long\u2010standing type 2 diabetes: analyses from the DECLARE\u2010TIMI 58 trial"], ["Harpreet S Bajaj", 2020, "Cardiovascular and renal benefits of dapagliflozin in patients with short and long\u2010standing type 2 diabetes: analyses from the DECLARE\u2010TIMI 58 trial"], ["Darren K McGuire", 2020, "Cardiovascular and renal benefits of dapagliflozin in patients with short and long\u2010standing type 2 diabetes: analyses from the DECLARE\u2010TIMI 58 trial"], ["Itamar Raz", 2020, "Cardiovascular and renal benefits of dapagliflozin in patients with short and long\u2010standing type 2 diabetes: analyses from the DECLARE\u2010TIMI 58 trial"], ["Sabina A Murphy", 2020, "Cardiovascular and renal benefits of dapagliflozin in patients with short and long\u2010standing type 2 diabetes: analyses from the DECLARE\u2010TIMI 58 trial"], ["Stephen D Wiviott", 2020, "Cardiovascular and renal benefits of dapagliflozin in patients with short and long\u2010standing type 2 diabetes: analyses from the DECLARE\u2010TIMI 58 trial"], ["Ilan Yanuv", 2020, "Cardiovascular and renal benefits of dapagliflozin in patients with short and long\u2010standing type 2 diabetes: analyses from the DECLARE\u2010TIMI 58 trial"], ["John PH Wilding", 2020, "Cardiovascular and renal benefits of dapagliflozin in patients with short and long\u2010standing type 2 diabetes: analyses from the DECLARE\u2010TIMI 58 trial"], ["Maja Bujas-Bobanovic", 2020, "Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab"], ["Jonas Mandel", 2020, "Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab"], ["Marja-Riitta Taskinen", 2020, "Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab"], ["Antonio J Vallejo-Vaz", 2020, "Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab"], ["Michelle Mocarski", 2020, "Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically \u2026"], ["Samuel Malkin", 2020, "Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically \u2026"], ["Barnaby Hunt", 2020, "Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically \u2026"], ["Alexandra Bargiota", 2020, "Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically \u2026"], ["Liana Billings", 2020, "Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically \u2026"], ["Alisa Schiffman", 2020, "Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically \u2026"], ["Anthony J Cannon", 2020, "Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically \u2026"], ["Ankur Doshi", 2020, "Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically \u2026"], ["Mattis Flyvholm Ranthe", 2020, "Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically \u2026"], ["Peter A Johansson", 2020, "Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE\u2013TIMI 58 Study"], ["Martin Fredriksson", 2020, "Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE\u2013TIMI 58 Study"], ["Ingrid AM Gause-Nilsson", 2020, "Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE\u2013TIMI 58 Study"], ["Erica L Goodrich", 2020, "Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE\u2013TIMI 58 Study"], ["Anna Maria Langkilde", 2020, "Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE\u2013TIMI 58 Study"], ["F Giorgino", 2020, "Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed\u2010ratio combination: a post hoc analysis of the LixiLan\u2010O \u2026"], ["JP Frias", 2020, "Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed\u2010ratio combination: a post hoc analysis of the LixiLan\u2010O \u2026"], ["A Saremi", 2020, "Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed\u2010ratio combination: a post hoc analysis of the LixiLan\u2010O \u2026"], ["J Chao", 2020, "Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed\u2010ratio combination: a post hoc analysis of the LixiLan\u2010O \u2026"], ["L Van Gaal", 2020, "Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed\u2010ratio combination: a post hoc analysis of the LixiLan\u2010O \u2026"], ["V Fonseca", 2020, "Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed\u2010ratio combination: a post hoc analysis of the LixiLan\u2010O \u2026"], ["JA Davidson", 2020, "Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed\u2010ratio combination: a post hoc analysis of the LixiLan\u2010O \u2026"], ["C Desouza", 2020, "Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed\u2010ratio combination: a post hoc analysis of the LixiLan\u2010O \u2026"], ["TA Dex", 2020, "Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed\u2010ratio combination: a post hoc analysis of the LixiLan\u2010O \u2026"], ["M Roberts", 2020, "Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed\u2010ratio combination: a post hoc analysis of the LixiLan\u2010O \u2026"], ["LA Leiter", 2020, "Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed\u2010ratio combination: a post hoc analysis of the LixiLan\u2010O \u2026"], ["Jennifer B Green", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Christopher B Granger", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Robert M Califf", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Matthew T Roe", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Marc A Pfeffer", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Todd Hobbs", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Jyothis Thomas George", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Rury R Holman", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Robert Temple", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Dave Demets", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Hertzel C Gerstein", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Abhinav Sharma", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Francesca C Lawson", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Yves Rosenberg", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Neha J Pagidipati", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Jane Reusch", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Jeffrey S Riesmeyer", 2020, "Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions"], ["Marc P Bonaca", 2020, "Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial"], ["Thomas A Zelniker", 2020, "Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial"], ["Robert G Kiss", 2020, "Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial"], ["Francisco Padilla", 2020, "Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial"], ["Andrzej Budaj", 2020, "Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial"], ["Remo Furtado", 2020, "Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial"], ["Ingrid Gause-Nilsson", 2020, "Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial"], ["Julia F Kuder", 2020, "Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial"], ["Thomas R Pieber", 2020, "Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial"], ["Steen Ladelund", 2020, "Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial"], ["Melissa V Hansen", 2020, "Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial"], ["Lone N Troelsen", 2020, "Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial"], ["Kamlesh Khunti", 2020, "Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial"], ["Simon Heller", 2020, "Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial"], ["David C Klonoff", 2020, "Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial"], ["Athena Philis-Tsimikas", 2020, "Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial"], ["ESG Stroes", 2020, "Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR \u2026"], ["AC Goldberg", 2020, "Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR \u2026"], ["Robert Hart", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Charles Messan Atisso", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Lars Ryd\u00e9n", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Patricio Lopez-Jaramillo", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Ignacio Conget", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Fady T Botros", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Mark Lakshmanan", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Alvaro Avezum", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Jonathan E Shaw", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["William C Cushman", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Theodora Temelkova-Kurktschiev", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Peter J Raubenheimer", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Petr Jansky", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Nicolae Hancu", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Stephanie Hall", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Ernesto Germ\u00e1n Cardona Mu\u00f1oz", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Matthew C Riddle", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Rafael Diaz", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Jan Basile", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Markolf Hanefeld", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Fernando Lanas", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Jeffrey Probstfield", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Wayne HH Sheu", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Leanne Dyal", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Matyas Keltai", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Nana Pogosova", 2020, "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial"], ["Richard Robson", 2020, "Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies"], ["John JP Kastelein", 2020, "Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies"], ["Michael G Collins", 2020, "Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies"], ["Peter LJ Wijngaard", 2020, "Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies"], ["Robert M Stoekenbroek", 2020, "Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies"], ["R Scott Wright", 2020, "Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies"], ["Ulf Landmesser", 2020, "Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies"], ["Cheryll Wills", 2019, "GOAL Canada: Physician Education and Support Can Improve Patient Management"], ["Mary Tan", 2019, "GOAL Canada: Physician Education and Support Can Improve Patient Management"], ["Shaun G Goodman", 2019, "GOAL Canada: Physician Education and Support Can Improve Patient Management"], ["Anatoly Langer", 2019, "GOAL Canada: Physician Education and Support Can Improve Patient Management"], ["Jean Gr\u00e9goire", 2019, "GOAL Canada: Physician Education and Support Can Improve Patient Management"], ["Peter J Lin", 2019, "GOAL Canada: Physician Education and Support Can Improve Patient Management"], ["James A Stone", 2019, "GOAL Canada: Physician Education and Support Can Improve Patient Management"], ["Caroline Spindler", 2019, "GOAL Canada: Physician Education and Support Can Improve Patient Management"], ["GB John Mancini", 2019, "GOAL Canada: Physician Education and Support Can Improve Patient Management"], ["Peter L Wijngaard", 2019, "Safety and Efficacy of Inclisiran in Patients With ASCVD and Elevated LDL Cholesterol-Results From the Phase 3 ORION-10 Trial"], ["Johannes J Kastelein Jr", 2019, "Safety and Efficacy of Inclisiran in Patients With ASCVD and Elevated LDL Cholesterol-Results From the Phase 3 ORION-10 Trial"], ["Wolfgang Koenig", 2019, "Safety and Efficacy of Inclisiran in Patients With ASCVD and Elevated LDL Cholesterol-Results From the Phase 3 ORION-10 Trial"], ["Frederick J Raal", 2019, "Safety and Efficacy of Inclisiran in Patients With ASCVD and Elevated LDL Cholesterol-Results From the Phase 3 ORION-10 Trial"], ["John L Sievenpiper", 2018, "1. STUDY TITLE"], ["Tauseef Khan", 2018, "1. STUDY TITLE"], ["Sabrina Ayoub-Charette", 2018, "1. STUDY TITLE"], ["Michael G Silverman", 2018, "Late-Breaking Clinical Trial: Novel Approaches to CV Prevention"], ["John P Wilding", 2018, "Late-Breaking Clinical Trial: Novel Approaches to CV Prevention"], ["Eri T Kato", 2018, "Late-Breaking Clinical Trial: Novel Approaches to CV Prevention"], ["Ingrid A Gause-Nilsson", 2018, "Late-Breaking Clinical Trial: Novel Approaches to CV Prevention"], ["Sai G Lambotharan", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["C David Mazer", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Peter Juni", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Arun C Partridge", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Christopher Bonneau", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Naveen Gupta", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Olugbenga O Bello", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["David W Dai", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Ehab Bakbak", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Andrew T Yana", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Tamique Mason", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Andrew H Williams", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Michael E Farkouh", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Ronald M Goldenberg", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Nathasha Dhingra", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Anna Slabiak", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Andrew Liuni", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Biswajit Chowdhury", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["David H Fitchett", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["LEADER Publication Committee on Behalf of the LEADER Trial Investigators", 2018, "Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from \u2026"], ["John B Buse", 2018, "Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from \u2026"], ["Richard E Pratley", 2018, "Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from \u2026"], ["S\u00f8ren Rasmussen", 2018, "Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from \u2026"], ["Michael A Nauck", 2018, "Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from \u2026"], ["Stephen C Bain", 2018, "Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from \u2026"], ["Neil R Poulter", 2018, "Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from \u2026"], ["Tea Monk Fries", 2018, "Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from \u2026"], ["Steven P Marso", 2018, "Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from \u2026"], ["David D \u00d8rsted", 2018, "Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from \u2026"], ["R Samuel", 2018, "Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials"], ["DG Karalis", 2018, "Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials"], ["PH Jones", 2018, "Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials"], ["J Mandel", 2018, "Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials"], ["A Letierce", 2018, "Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials"], ["M Bujas\u2010Bobanovic", 2018, "Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials"], ["FJ Tinahones", 2018, "Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials"], ["Marina V Shestakova", 2018, "Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial"], ["Ilhan Satman", 2018, "Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial"], ["E Bayram Llamas", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Elliott", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["A Stasiewski", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["G Melendez Mier", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["R Cutfield", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["A Hess", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["E Mirek-Bryniarska", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["R Jayasinghe", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Proietto", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["R Korzeniak", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["F Lanas", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Liutkus", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Berlingieri", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["P Manning", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Neil Weissman", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["S Kouz", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["D Cross", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["RE Oqueli", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Cha", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["A Stankiewicz", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["M Wujkowski", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Mikhail Ruda", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["A Bell", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["R Leikis", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Jose Carlos Nicolau", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Jindrich Spinar", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["M Williams", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["P Garrahy", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Anthony Keech", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Armando Garcia-Castillo", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["M William", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Benatar", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Korecki", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["S Vizel", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Silvio Inzucchi", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["D Savard", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["H Khandwala", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["V Pandith", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Jamie Dwyer", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["H Bajaj", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["M Arstall", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["D Ninio", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["R Chehayeb", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["BK Nirmalaraj", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Ramon Corbalan", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Y Beaudry", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["E Lopez Rosas", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["M Suranyi", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["I Bata", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["S Ross", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["R Lehman", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["T \u017bechowicz", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["K Cymerman", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["M Hartleib", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["M Bronisz", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Cobos", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["H Hart", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Christian Hamm", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["G Llamas Esperon", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["C Fortin", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["D Twum-Barima", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["P Purnell", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["M Heffernan", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["C Conejeros", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Conville Brown", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Ton Oude Ophuis", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Selvanayagam", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Benjamin M Scirica", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["F Blouin", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Harvey D White", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["I Ternouth", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["D Zytkiewicz-Jaruga", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["R Labonte", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["R Witek", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["F St Maurice", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["D Shukla", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["D Scott", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["R Moses", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["F de Looze", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Horowitz", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["V Saavedra Guajardo", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Wenfeng Miao", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["G Wong", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["E Cardona Mu\u00f1oz", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["P Ko\u0144czakowski", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["M Le May", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J B\u00e9dard", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["K Ferrier", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["A Bochenek", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Andrew Satlin", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["C Constance", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["P Mi\u0119kus", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Shobha Dhadda", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["M Worthley", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Steven R Smith", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["C Pincetti", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Tushar Patel", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Milan Gupta", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["G Godoy", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["S Wharton", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Erin A Bohula", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Anthony C Keech", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Carlos Perdomo", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Jamie P Dwyer", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Bruce Francis", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Lee Kaplan", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["M Og\u00f3rek", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["L Perez", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["P Poirier", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["N Gupta", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["AS Pandey", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["R Scott", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["P Varleta", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["E Krzy\u017cag\u00f3rska", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Skierkowska", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["K \u0141anda", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["M Piepiorka", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["A Whelan", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Kauski Ray", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["A Lee", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["R Goldenberg", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["M d'Emden", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Christian T Ruff", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Silvio E Inzucchi", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["R Garcia", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Z Yared", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["E Szyprowska", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["G Ramos", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Estella Kanevsky", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["D Colquhoun", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["R Aronson", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["L Paw\u0142owicz", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["G Wittert", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Amerena", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["\u00c9 St-Amour", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["B Ajala", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Garza Ruiz", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["S Wilson", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["A Jain", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["P Blombery", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["J Waites", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["I Teitelbaum", 2018, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["Russell J de Souza", 2018, "Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies"], ["Vanessa Ha", 2018, "Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies"], ["Thomas MS Wolever", 2018, "Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies"], ["Effie Viguiliouk", 2018, "Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies"], ["Cyril WC Kendall", 2018, "Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies"], ["Adrian I Cozma", 2018, "Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies"], ["Sonia Blanco Mejia", 2018, "Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies"], ["Vladimir Vuksan", 2018, "Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies"], ["Vivian L Choo", 2018, "Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies"], ["Tauseef A Khan", 2018, "Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies"], ["David JA Jenkins", 2018, "Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies"], ["John J Kastelein", 2018, "Relationship Between Baseline PCSK9 and LDL-C Reduction in Response to the Investigational RNAi Therapeutic Inclisiran"], ["John Kastelein", 2018, "Effects of an Investigational RNAi Therapeutic Targeting PCSK9 on Immunological and Hematological Parameters: A Safety Analysis From ORION-1"], ["Arash Haghikia", 2018, "Effects of an Investigational RNAi Therapeutic Targeting PCSK9 on Immunological and Hematological Parameters: A Safety Analysis From ORION-1"], ["RS Wright", 2018, "Effects of an Investigational RNAi Therapeutic Targeting PCSK9 on Immunological and Hematological Parameters: A Safety Analysis From ORION-1"], ["Peter Wijngaard", 2018, "Effects of an Investigational RNAi Therapeutic Targeting PCSK9 on Immunological and Hematological Parameters: A Safety Analysis From ORION-1"], ["S\u00f8ren Lindberg", 2018, "The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: Analysis of \u2026"], ["Stephen Bain", 2018, "The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: Analysis of \u2026"], ["Hrvoje Vrazic", 2018, "The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: Analysis of \u2026"], ["Richard Pratley", 2018, "The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: Analysis of \u2026"], ["John Buse", 2018, "The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: Analysis of \u2026"], ["S\u00f8re Lindberg", 2018, "The glucagon-like peptide-1 receptor agonists liraglutide and semaglutide improve cardiovascular and renal outcomes across most body mass index categories in type 2 diabetes \u2026"], ["Catherine R Braunstein", 2018, "The effect of small doses of fructose and its epimers on glycemic control: a systematic review and meta-analysis of controlled feeding trials"], ["Thomas Wolever", 2018, "The effect of small doses of fructose and its epimers on glycemic control: a systematic review and meta-analysis of controlled feeding trials"], ["Jarvis C Noronha", 2018, "The effect of small doses of fructose and its epimers on glycemic control: a systematic review and meta-analysis of controlled feeding trials"], ["S Janmohamed", 2018, "Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double \u2026"], ["JB Green", 2018, "Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double \u2026"], ["JJV McMurray", 2018, "Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double \u2026"], ["KN Sigmon", 2018, "Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double \u2026"], ["AF Hernandez", 2018, "Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double \u2026"], ["AE Rosenberg", 2018, "Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double \u2026"], ["MC Somerville", 2018, "Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double \u2026"], ["RB D\u2019Agostino Sr", 2018, "Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double \u2026"], ["S Del Prato", 2018, "Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double \u2026"], ["NP Jones", 2018, "Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double \u2026"], ["KM Thorpe", 2018, "Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double \u2026"], ["CB Granger", 2018, "Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double \u2026"], ["Christina Howell", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Alejandro Chertkoff", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Kathleen Dungan", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Jennifer Roush", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Moon Kyu Lee", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Tuan Chau", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Maria Ulla", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Shaun Goodman", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Tamra Christian", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Andrea Giaccari", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Boris Mankovsky", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Kristina N Sigmon", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Rury Holman", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Louie Tirador", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Renato Lopes", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Marsha Marquess", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Matthew Riddle", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Susan Bartone", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Ilias Migdalis", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Martin Haluzik", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Karen Alexander", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Jesus Cuadrado", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Tracy Gentry", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Pierluigi Tricoci", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Larry Distiller", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Robin Mathews", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Anne E Rosenberg", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Joanna Cole", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Rajendra Mehta", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Renee Rethaford", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Miguel Pinto", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Suphot Srimahachota", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Georgina Sposetti", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Jose Lopez-Sendon", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Keith Dombrowski", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Kourtnei James", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Cesar Zaidman", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Silvia Orio", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Matthew Roe", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Gustavo Frechtel", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Fernando Verra", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Irene Hramiak", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Andrea Dominguez", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Choon Beng Kathryn Tan", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Jose Fretes", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Sreekanth Vemulapalli", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Silvina Zabalua", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["David Kong", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Robert Enns", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Gerald Bloomfield", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Jay Shavadia", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["William Schuyler Jones", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Wendy Jenkins", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Kim Brown", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["David DeMets", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Bruno Guerci", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Marcos Litvak", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Rob Harrison", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Aditya Mandawat", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Pedro Calella", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Ralph B D'Agostino", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Natalia Garrido Santos", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Adam Devore", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Laura Maffei", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Firas Al Kawas", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Chantal Mathieu", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Matt Bailey", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Luis De Loredo", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Andr\u00e9 Scheen", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["S\u00f8ren Galatius", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Teresa Akers", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Corinne Debroye", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Andres Alvarisqueta", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Jorge Baldovino", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Mikhail Kosiborod", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Zubin Eapen", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Matthew C Somerville", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Dedrick Jordan", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Isaac Sinay", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Diego Besada", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Diego Mohr Gasparini", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Salim Janmohamed", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Karl M Thorpe", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Jenny Rich", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Michelle Anderson", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Patricia Casta\u00f1o", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Francis Duyck", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Chris Vercammen", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Bjorn Eliasson", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Trevorlyn Haddock", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Matt Wilson", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Jeannie Collier", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Connie Pope", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Brad Kolls", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Darren McGuire", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["M Angelyn Bethel", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Ralph B D'Agostino Sr", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Kare Birkeland", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Lauren Cooper", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Maria Cecilia Cantero", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Velichka Damyanova", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Daniel Friedman", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Jean Pesarchick", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Gyozo Kocsis", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Laurent Crenier", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Patricia Endsley", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Rebecca Coker", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Jorgelina Sala", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Deb Greene", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Chiara Melloni", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Nigel P Jones", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Martyna Olesinska-Mader", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Maria Vanesa Espa\u00f1ol", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Patricia Guimaraes", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Andrew Ambrosy", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Stephen Greene", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Megan Johnson", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Ernesto German Cardona Mu\u00f1oz", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Jan Cornel", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Joaquin Gonzalez", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Natacha Maldonado", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Adrian F Hernandez", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Chetan Patel", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Pablo Schygiel", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Thomas Povsic", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Allegra Stone", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Gail Beaulieu", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Ghazala Haque", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Chern-En Chiang", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Betsy Thomas", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Federico Perez Manghi", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Victor Yordanov", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Michael Nauck", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Marina Shestakova", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Kathleen Perez", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Nelson Rodriguez Papini", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Juan Loureyro", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Beth Vandyne", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Luc Van Gaal", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Hernan Finkelstein", 2018, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Diane Hua-Stewart", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Diana Sherifali", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Simon Bacon", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Peter Selby", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Mary L\u2019Abbe", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Glen J Pearson", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Jack V Tu", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Eileen O\u2019Meara", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Justin A Ezekowitz", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Doreen M Rabi", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Todd Anderson", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Patty Lindsay", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Peter P Liu", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Alice YY Cheng", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Sheldon W Tobe", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Kimberly M Walker", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Stella S Daskalopoulou", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Jean C Gregoire", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Gord Gubitz", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["David CW Lau", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Karim Keshavjee", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Sean Wharton", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Rahul Jain", 2018, "Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update"], ["Heidrun Bosch-Traberg", 2018, "Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use: results \u2026"], ["Steve Marso", 2018, "Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use: results \u2026"], ["LEADER Publication Committee on behalf of the LEADER Trial Investigators", 2018, "Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use: results \u2026"], ["Marie M Michelsen", 2018, "Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use: results \u2026"], ["Robert A Hegele", 2018, "Erratum to \u201cDyslipidemia\u201d: Canadian Journal of Diabetes 2018; 42 (S1): S178-S185"], ["GB Mancini", 2018, "Dyslipidemia (vol 42, pg S178, 2018)"], ["DL Bhatt", 2018, "Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial"], ["S Rasmussen", 2018, "Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial"], ["RE Pratley", 2018, "Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial"], ["MM Michelsen", 2018, "Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial"], ["T Monk Fries", 2018, "Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial"], ["B Zinman", 2018, "Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial"], ["MA Nauck", 2018, "Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial"], ["S Verma", 2018, "Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial"], ["SC Bain", 2018, "Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial"], ["J Mann", 2018, "Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial"], ["T Dex", 2018, "HbA (1c) target attainment in patients with type 2 diabetes receiving iGlarLixi who reach postprandial glucose and fasting plasma glucose targets in the LixiLan-L trial"], ["J Davidson", 2018, "HbA (1c) target attainment in patients with type 2 diabetes receiving iGlarLixi who reach postprandial glucose and fasting plasma glucose targets in the LixiLan-L trial"], ["L Leiter", 2018, "HbA (1c) target attainment in patients with type 2 diabetes receiving iGlarLixi who reach postprandial glucose and fasting plasma glucose targets in the LixiLan-L trial"], ["H Bosch-Traberg", 2018, "Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial"], ["H Frimer-Larsen", 2018, "Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial"], ["C Mazer", 2018, "Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial"], ["J Buse", 2018, "Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial"], ["S Marso", 2018, "Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial"], ["Mattis F Ranthe", 2018, "Patients with Type 2 Diabetes Treated with IDegLira Have a Greater Chance of Achieving A1C Targets Without Hypoglycemia and Weight Gain Than with Basal Insulin or Basal-Bolus \u2026"], ["Marsha Haynes", 2018, "Patients with Type 2 Diabetes Treated with IDegLira Have a Greater Chance of Achieving A1C Targets Without Hypoglycemia and Weight Gain Than with Basal Insulin or Basal-Bolus \u2026"], ["Leonard E Egede", 2018, "Patients with Type 2 Diabetes Treated with IDegLira Have a Greater Chance of Achieving A1C Targets Without Hypoglycemia and Weight Gain Than with Basal Insulin or Basal-Bolus \u2026"], ["Nanna Leonora Lausvig", 2018, "More Subjects Achieved Composite Reductions of\u2265 1% HbA1C,\u2265 5% Body Weight and\u2265 5 mmHg Systolic Blood Pressure with Semaglutide vs. Comparators (SUSTAIN 1\u20135, 7)"], ["Juris Meier", 2018, "More Subjects Achieved Composite Reductions of\u2265 1% HbA1C,\u2265 5% Body Weight and\u2265 5 mmHg Systolic Blood Pressure with Semaglutide vs. Comparators (SUSTAIN 1\u20135, 7)"], ["Vanita R Aroda", 2018, "More Subjects Achieved Composite Reductions of\u2265 1% HbA1C,\u2265 5% Body Weight and\u2265 5 mmHg Systolic Blood Pressure with Semaglutide vs. Comparators (SUSTAIN 1\u20135, 7)"], ["Filip Krag Knop", 2018, "More Subjects Achieved Composite Reductions of\u2265 1% HbA1C,\u2265 5% Body Weight and\u2265 5 mmHg Systolic Blood Pressure with Semaglutide vs. Comparators (SUSTAIN 1\u20135, 7)"], ["S\u00f8ren Ils\u00f8e Moreno", 2018, "Once-weekly semaglutide provides better value for money than a broad range of other type 2 diabetes treatments in Canada: a relative cost of control analysis"], ["Jonas H\u00e5kan-Bloch", 2018, "Once-weekly semaglutide provides better value for money than a broad range of other type 2 diabetes treatments in Canada: a relative cost of control analysis"], ["Aiden Ranke Liu", 2018, "Once-weekly semaglutide provides better value for money than a broad range of other type 2 diabetes treatments in Canada: a relative cost of control analysis"], ["Pierre Johansen", 2018, "Once-weekly semaglutide provides better value for money than a broad range of other type 2 diabetes treatments in Canada: a relative cost of control analysis"], ["Peter Galthen Bech", 2018, "Once-weekly semaglutide provides better value for money than a broad range of other type 2 diabetes treatments in Canada: a relative cost of control analysis"], ["P Lin", 2018, "GUIDELINES ORIENTED APPROACH TO LIPID LOWERING (GOAL) MEDICAL PRACTICE ACTIVITY (MPA) TO ACHIEVE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGETS"], ["C Spindler", 2018, "GUIDELINES ORIENTED APPROACH TO LIPID LOWERING (GOAL) MEDICAL PRACTICE ACTIVITY (MPA) TO ACHIEVE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGETS"], ["G Mancini", 2018, "GUIDELINES ORIENTED APPROACH TO LIPID LOWERING (GOAL) MEDICAL PRACTICE ACTIVITY (MPA) TO ACHIEVE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGETS"], ["A Langer", 2018, "GUIDELINES ORIENTED APPROACH TO LIPID LOWERING (GOAL) MEDICAL PRACTICE ACTIVITY (MPA) TO ACHIEVE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGETS"], ["M Tan", 2018, "GUIDELINES ORIENTED APPROACH TO LIPID LOWERING (GOAL) MEDICAL PRACTICE ACTIVITY (MPA) TO ACHIEVE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGETS"], ["R Dufour", 2018, "GUIDELINES ORIENTED APPROACH TO LIPID LOWERING (GOAL) MEDICAL PRACTICE ACTIVITY (MPA) TO ACHIEVE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGETS"], ["J Gregoire", 2018, "GUIDELINES ORIENTED APPROACH TO LIPID LOWERING (GOAL) MEDICAL PRACTICE ACTIVITY (MPA) TO ACHIEVE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGETS"], ["S Goodman", 2018, "GUIDELINES ORIENTED APPROACH TO LIPID LOWERING (GOAL) MEDICAL PRACTICE ACTIVITY (MPA) TO ACHIEVE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGETS"], ["C Wills", 2018, "GUIDELINES ORIENTED APPROACH TO LIPID LOWERING (GOAL) MEDICAL PRACTICE ACTIVITY (MPA) TO ACHIEVE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGETS"], ["M Nauck", 2018, "Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial"], ["M Michelsen", 2018, "Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial"], ["D Bhatt", 2018, "Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial"], ["S Bain", 2018, "Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial"], ["S Madsbad", 2018, "SEMAGLUTIDE CONSISTENTLY REDUCES CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES REGARDLESS OF BASELINE CARDIOVASCULAR RISK LEVEL: POST HOC ANALYSES OF THE SUSTAIN TRIAL \u2026"], ["M Warren", 2018, "SEMAGLUTIDE CONSISTENTLY REDUCES CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES REGARDLESS OF BASELINE CARDIOVASCULAR RISK LEVEL: POST HOC ANALYSES OF THE SUSTAIN TRIAL \u2026"], ["H Vrazic", 2018, "SEMAGLUTIDE CONSISTENTLY REDUCES CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES REGARDLESS OF BASELINE CARDIOVASCULAR RISK LEVEL: POST HOC ANALYSES OF THE SUSTAIN TRIAL \u2026"], ["A Holst", 2018, "SEMAGLUTIDE CONSISTENTLY REDUCES CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES REGARDLESS OF BASELINE CARDIOVASCULAR RISK LEVEL: POST HOC ANALYSES OF THE SUSTAIN TRIAL \u2026"], ["R R\u00e9a", 2018, "SEMAGLUTIDE CONSISTENTLY REDUCES CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES REGARDLESS OF BASELINE CARDIOVASCULAR RISK LEVEL: POST HOC ANALYSES OF THE SUSTAIN TRIAL \u2026"], ["Q Liu", 2018, "IMPORTANT FOOD SOURCES OF FRUCTOSE-CONTAINING SUGARS AND CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE COHORT STUDIES"], ["T Khan", 2018, "IMPORTANT FOOD SOURCES OF FRUCTOSE-CONTAINING SUGARS AND CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE COHORT STUDIES"], ["T Wolever", 2018, "IMPORTANT FOOD SOURCES OF FRUCTOSE-CONTAINING SUGARS AND CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE COHORT STUDIES"], ["R de Souza", 2018, "IMPORTANT FOOD SOURCES OF FRUCTOSE-CONTAINING SUGARS AND CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE COHORT STUDIES"], ["C Kendall", 2018, "IMPORTANT FOOD SOURCES OF FRUCTOSE-CONTAINING SUGARS AND CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE COHORT STUDIES"], ["S Blanco Mejia", 2018, "IMPORTANT FOOD SOURCES OF FRUCTOSE-CONTAINING SUGARS AND CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE COHORT STUDIES"], ["J Sievenpiper", 2018, "IMPORTANT FOOD SOURCES OF FRUCTOSE-CONTAINING SUGARS AND CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE COHORT STUDIES"], ["A Zurbau", 2018, "IMPORTANT FOOD SOURCES OF FRUCTOSE-CONTAINING SUGARS AND CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE COHORT STUDIES"], ["S Ayoub-Charette", 2018, "IMPORTANT FOOD SOURCES OF FRUCTOSE-CONTAINING SUGARS AND CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE COHORT STUDIES"], ["F Au-Yeung", 2018, "IMPORTANT FOOD SOURCES OF FRUCTOSE-CONTAINING SUGARS AND CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE COHORT STUDIES"], ["S Lindbergh", 2018, "More subjects achieved composite reductions of>= 1% HbA (1c),>= 5% body weight and>= 5 mmHg SBP with semaglutide vs comparators across the SUSTAIN 1-5 and 7 trials"], ["FK Knop", 2018, "More subjects achieved composite reductions of>= 1% HbA (1c),>= 5% body weight and>= 5 mmHg SBP with semaglutide vs comparators across the SUSTAIN 1-5 and 7 trials"], ["J Ferlov Schwensen", 2018, "More subjects achieved composite reductions of>= 1% HbA (1c),>= 5% body weight and>= 5 mmHg SBP with semaglutide vs comparators across the SUSTAIN 1-5 and 7 trials"], ["VR Aroda", 2018, "More subjects achieved composite reductions of>= 1% HbA (1c),>= 5% body weight and>= 5 mmHg SBP with semaglutide vs comparators across the SUSTAIN 1-5 and 7 trials"], ["JJ Meier", 2018, "More subjects achieved composite reductions of>= 1% HbA (1c),>= 5% body weight and>= 5 mmHg SBP with semaglutide vs comparators across the SUSTAIN 1-5 and 7 trials"], ["KM Dungan", 2018, "More subjects achieved composite reductions of>= 1% HbA (1c),>= 5% body weight and>= 5 mmHg SBP with semaglutide vs comparators across the SUSTAIN 1-5 and 7 trials"], ["NL Lausvig", 2018, "More subjects achieved composite reductions of>= 1% HbA (1c),>= 5% body weight and>= 5 mmHg SBP with semaglutide vs comparators across the SUSTAIN 1-5 and 7 trials"], ["Breay Paty", 2018, "CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management"], ["Kim Connelly", 2018, "CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management"], ["Alice Y Cheng", 2018, "CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management"], ["Vincent Woo", 2018, "CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management"], ["David Fitchett", 2018, "CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management"], ["Paul Poirier", 2018, "CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management"], ["David Thompson", 2018, "CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management"], ["Jean-Francois Yale", 2018, "CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management"], ["Eva Lonn", 2018, "CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management"], ["James Stone", 2018, "CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management"], ["Ronald Goldenberg", 2018, "CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management"], ["Jeffrey C Hanselman", 2018, "Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study"], ["Xin Zhao", 2018, "Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study"], ["Norman E Lepor", 2018, "Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study"], ["Maciej Banach", 2018, "Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study"], ["Om P Ganda", 2018, "Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials"], ["Maja Bujas\u2010Bobanovic", 2018, "Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials"], ["Andrew Koren", 2018, "Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials"], ["Santosh K Sanganalmath", 2018, "Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials"], ["Jorge Plutzky", 2018, "Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials"], ["Andrea J Glenn", 2018, "The effect of small doses of fructose and allulose on postprandial glucose metabolism in type 2 diabetes: A double\u2010blind, randomized, controlled, acute feeding, equivalence trial"], ["Rebecca Noseworthy", 2018, "The effect of small doses of fructose and allulose on postprandial glucose metabolism in type 2 diabetes: A double\u2010blind, randomized, controlled, acute feeding, equivalence trial"], ["Julia Kuder", 2018, "Cardiovascular safety of lorcaserin in overweight or obese patients"], ["Arman Qamar", 2018, "Cardiovascular safety of lorcaserin in overweight or obese patients"], ["Neil J Weissman", 2018, "Cardiovascular safety of lorcaserin in overweight or obese patients"], ["Christina L Fanola", 2018, "Cardiovascular safety of lorcaserin in overweight or obese patients"], ["KyungAh Im", 2018, "Cardiovascular safety of lorcaserin in overweight or obese patients"], ["A Gaarsdal Holst", 2018, "Sustain 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes"], ["J Seufert", 2018, "Sustain 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes"], ["LH Damgaard", 2018, "Sustain 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes"], ["E Jodar", 2018, "Sustain 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes"], ["S Bellary", 2018, "Sustain 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes"], ["Rachael Russell", 2018, "Harmony outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus \u2026"], ["Chris B Granger", 2018, "Harmony outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus \u2026"], ["Drusilla Noronha", 2018, "Harmony outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus \u2026"], ["Ralph B D\u2019Agostino", 2018, "Harmony outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus \u2026"], ["Kristina Sigmon", 2018, "Harmony outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus \u2026"], ["Michel Marre", 2018, "The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents"], ["Siew Pheng Chan", 2018, "The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents"], ["Giorgio Sesti", 2018, "The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents"], ["Stephen Colagiuri", 2018, "The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents"], ["David Matthews", 2018, "The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents"], ["Anders Gaarsdal Holst", 2018, "Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials"], ["Bo Ahr\u00e9n", 2018, "Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials"], ["Guillaume Charpentier", 2018, "Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials"], ["Stephen L Atkin", 2018, "Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials"], ["Mark L Warren", 2018, "Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials"], ["Sune Birch", 2018, "Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials"], ["Gilles R Dagenais", 2018, "Effects of Lipid\u2010Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE\u20103 Trial"], ["Mahshid Dehghan", 2018, "Effects of Lipid\u2010Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE\u20103 Trial"], ["Jackie Bosch", 2018, "Effects of Lipid\u2010Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE\u20103 Trial"], ["Salim Yusuf", 2018, "Effects of Lipid\u2010Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE\u20103 Trial"], ["Patricio Lopez\u2010Jaramillo", 2018, "Effects of Lipid\u2010Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE\u20103 Trial"], ["Hyejung Jung", 2018, "Effects of Lipid\u2010Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE\u20103 Trial"], ["Peter M Bogaty", 2018, "Effects of Lipid\u2010Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE\u20103 Trial"], ["Claes Held", 2018, "Effects of Lipid\u2010Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE\u20103 Trial"], ["William D Toff", 2018, "Effects of Lipid\u2010Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE\u20103 Trial"], ["Maty\u00e0s Keltai", 2018, "Effects of Lipid\u2010Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE\u20103 Trial"], ["RM Stoekenbroek", 2018, "Effect of an RNAi therapeutic targeting PCSK9 on atherogenic lipoproteins: Pre-specified secondary endpoints in orion 1"], ["D Kallend", 2018, "Effect of an RNAi therapeutic targeting PCSK9 on atherogenic lipoproteins: Pre-specified secondary endpoints in orion 1"], ["JJP Kastelein", 2018, "Effect of an RNAi therapeutic targeting PCSK9 on atherogenic lipoproteins: Pre-specified secondary endpoints in orion 1"], ["U Landmesser", 2018, "Effect of an RNAi therapeutic targeting PCSK9 on atherogenic lipoproteins: Pre-specified secondary endpoints in orion 1"], ["P Wijngaard", 2018, "Effect of an RNAi therapeutic targeting PCSK9 on atherogenic lipoproteins: Pre-specified secondary endpoints in orion 1"], ["K Ray", 2018, "Effect of an RNAi therapeutic targeting PCSK9 on atherogenic lipoproteins: Pre-specified secondary endpoints in orion 1"], ["R Scott-Wright", 2018, "Effect of an RNAi therapeutic targeting PCSK9 on atherogenic lipoproteins: Pre-specified secondary endpoints in orion 1"], ["LEADER Publication Committee", 2018, "P2858 Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial"], ["CD Mazer", 2018, "P2858 Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial"], ["LEADER Trial Investigators", 2018, "P2858 Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial"], ["Michael J Davies", 2018, "Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes"], ["Jimmy Ren", 2018, "Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes"], ["W Timothy Garvey", 2018, "Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes"], ["James List", 2018, "Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes"], ["Ujjwala Vijapurkar", 2018, "Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes"], ["Robert Cuddihy", 2018, "Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes"], ["Alberico L Catapano", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Terry A Jacobson", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Alberto Corsini", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Erik S Stroes", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Michael Roden", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Paul D Thompson", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Jane K Stock", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Winfried M\u00e4rz", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Eric Bruckert", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Georgirene D Vladutiu", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Ronald M Krauss", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Lale Tokg\u00f6zo\u011flu", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Raul D Santos", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["European Atherosclerosis Society Consensus Panel", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Olov Wiklund", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Henry N Ginsberg", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Guy De Backer", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["B\u00f8rge G Nordestgaard", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Evan A Stein", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["G Kees Hovingh", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["M John Chapman", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Baris Gencer", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Ulrich Laufs", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Fran\u00e7ois Mach", 2018, "Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract"], ["Jeong-Gun Park", 2018, "Inflammatory and cholesterol risk in the FOURIER trial"], ["Armando Lira Pineda", 2018, "Inflammatory and cholesterol risk in the FOURIER trial"], ["Huei Wang", 2018, "Inflammatory and cholesterol risk in the FOURIER trial"], ["Terje R Pedersen", 2018, "Inflammatory and cholesterol risk in the FOURIER trial"], ["Robert P Giugliano", 2018, "Inflammatory and cholesterol risk in the FOURIER trial"], ["Peter S Sever", 2018, "Inflammatory and cholesterol risk in the FOURIER trial"], ["Narimon Honarpour", 2018, "Inflammatory and cholesterol risk in the FOURIER trial"], ["Aramesh Saremi", 2018, "Glycemic Target Attainment in Insulin-Na\u00efve Patients with T2D Receiving iGlarLixi"], ["Terry A Dex", 2018, "Glycemic Target Attainment in Insulin-Na\u00efve Patients with T2D Receiving iGlarLixi"], ["Francesco Giorgino", 2018, "Glycemic Target Attainment in Insulin-Na\u00efve Patients with T2D Receiving iGlarLixi"], ["Cyrus Desouza", 2018, "Glycemic Target Attainment in Insulin-Na\u00efve Patients with T2D Receiving iGlarLixi"], ["Juan P Frias", 2018, "Glycemic Target Attainment in Insulin-Na\u00efve Patients with T2D Receiving iGlarLixi"], ["Jason Chao", 2018, "Glycemic Target Attainment in Insulin-Na\u00efve Patients with T2D Receiving iGlarLixi"], ["Michelle Roberts", 2018, "Glycemic Target Attainment in Insulin-Na\u00efve Patients with T2D Receiving iGlarLixi"], ["Vivian Fonseca", 2018, "Glycemic Target Attainment in Insulin-Na\u00efve Patients with T2D Receiving iGlarLixi"], ["Pierre Serusclat", 2018, "Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Target\u2014Analyses from the DUAL Program"], ["Sultan Linjawi", 2018, "Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Target\u2014Analyses from the DUAL Program"], ["Bue F Agner", 2018, "Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Target\u2014Analyses from the DUAL Program"], ["Trine Hansen", 2018, "Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Target\u2014Analyses from the DUAL Program"], ["Luigi Meneghini", 2018, "Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Target\u2014Analyses from the DUAL Program"], ["TINA VILSB\u00d8LL", 2018, "Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Target\u2014Analyses from the DUAL Program"], ["Filip K Knop", 2018, "More Subjects Achieved Composite Reductions of= 1% HbA1c,= 5% Body Weight, and= 5 mmHg SBP with Semaglutide vs. Comparators (SUSTAIN 1-5, 7)"], ["Nanna L Lausvig", 2018, "More Subjects Achieved Composite Reductions of= 1% HbA1c,= 5% Body Weight, and= 5 mmHg SBP with Semaglutide vs. Comparators (SUSTAIN 1-5, 7)"], ["Vanita Aroda", 2018, "More Subjects Achieved Composite Reductions of= 1% HbA1c,= 5% Body Weight, and= 5 mmHg SBP with Semaglutide vs. Comparators (SUSTAIN 1-5, 7)"], ["Juris J Meier", 2018, "More Subjects Achieved Composite Reductions of= 1% HbA1c,= 5% Body Weight, and= 5 mmHg SBP with Semaglutide vs. Comparators (SUSTAIN 1-5, 7)"], ["Kathleen M Dungan", 2018, "More Subjects Achieved Composite Reductions of= 1% HbA1c,= 5% Body Weight, and= 5 mmHg SBP with Semaglutide vs. Comparators (SUSTAIN 1-5, 7)"], ["S\u00d8REN LINDBERG", 2018, "More Subjects Achieved Composite Reductions of= 1% HbA1c,= 5% Body Weight, and= 5 mmHg SBP with Semaglutide vs. Comparators (SUSTAIN 1-5, 7)"], ["Robert R Henry", 2018, "Alirocumab Add-on Therapy Versus Control in Individuals with Type 2 DM and ASCVD: ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN"], ["Robert S Rosenson", 2018, "Characteristics of Patients in the 10th and 90th Percentile of LDL-C Reductions with Alirocumab: ODYSSEY Pooled Analyses"], ["Michael J Louie", 2018, "Characteristics of Patients in the 10th and 90th Percentile of LDL-C Reductions with Alirocumab: ODYSSEY Pooled Analyses"], ["Daniel J Rader", 2018, "Characteristics of Patients in the 10th and 90th Percentile of LDL-C Reductions with Alirocumab: ODYSSEY Pooled Analyses"], ["Desmond Thompson", 2018, "Characteristics of Patients in the 10th and 90th Percentile of LDL-C Reductions with Alirocumab: ODYSSEY Pooled Analyses"], ["Eli M Roth", 2018, "Characteristics of Patients in the 10th and 90th Percentile of LDL-C Reductions with Alirocumab: ODYSSEY Pooled Analyses"], ["Marie T Baccara-Dinet", 2018, "Characteristics of Patients in the 10th and 90th Percentile of LDL-C Reductions with Alirocumab: ODYSSEY Pooled Analyses"], ["Harold E Bays", 2018, "Characteristics of Patients in the 10th and 90th Percentile of LDL-C Reductions with Alirocumab: ODYSSEY Pooled Analyses"], ["Dirk M\u00fcller\u2010Wieland", 2018, "Alirocumab vs usual lipid\u2010lowering care as add\u2010on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM\u2010DYSLIPIDEMIA randomized trial"], ["Sameer Bansilal", 2018, "The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)\u2013TIMI 58 Trial"], ["Ildiko Lingvay", 2018, "Use of GLP-1 RAs in cardiovascular disease prevention: a practical guide"], ["Johannes FE Mann", 2018, "Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: results of the LEADER trial"], ["Raj S Padwal", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Norman RC Campbell", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Jonathan G Howlett", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Janis Dionne", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Philip A McFarlane", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Guy Tremblay", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Alexander A Leung", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Theodore H Wein", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Kaberi Dasgupta", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Praveena Sivapalan", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Pavel Hamet", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Hypertension Canada", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Simon L Bacon", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Jean C Gr\u00e9goire", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Alain Milot", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Anne-Marie C\u00f4t\u00e9", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Kim L Lavoie", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Luc Trudeau", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Sonia Butalia", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Ally PH Prebtani", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Steven E Gryn", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Thalia Field", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Marcel Ruzicka", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Mark Gelfer", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Patrice Lindsay", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Michael D Hill", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Karen C Tran", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Ashkan Shoamanesh", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Richard Lewanczuk", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Kara A Nerenberg", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Tavis S Campbell", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Charlotte Jones", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Laura M Kuyper", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Ellen Burgess", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Laura A Magee", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["S Brian Penner", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Kevin C Harris", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Jonathan Y Gabor", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Andrew Don-Wauchope", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["George Honos", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Robert J Herman", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Janusz Feber", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Ernesto L Schiffrin", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["GV Ramesh Prasad", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Michael Roerecke", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Alexander G Logan", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Raymond R Townsend", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["George K Dresser", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Evelyne Rey", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Luc Poirier", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Maxime Lamarre-Cliche", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Mike Sharma", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Ross D Feldman", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Michel Vall\u00e9e", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Cedric Edwards", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Lyne Cloutier", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Meranda Nakhla", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Gregory Kline", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Simon W Rabkin", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Kerry McBrien", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Janusz Kaczorowski", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Gordon W Moe", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Kelly B Zarnke", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Peter Bolli", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Genevi\u00e8ve Benoit", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Swapnil Hiremath", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Tabassum Firoz", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Steven Grover", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Paul Oh", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Donna McLean", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Andrew Pipe", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Joanne Arcand", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Anne Fournier", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Ross T Tsuyuki", 2018, "Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children"], ["Anna M Langkilde", 2018, "DECLARE\u2010TIMI 58: participants\u2019 baseline characteristics"], ["Jasmine Grenier", 2018, "Blood pressure management in adults with type 2 diabetes: Insights from the Diabetes Mellitus Status in Canada (DM-SCAN) Survey"], ["Thomas Ransom", 2018, "Blood pressure management in adults with type 2 diabetes: Insights from the Diabetes Mellitus Status in Canada (DM-SCAN) Survey"], ["Mary K Tan", 2018, "Blood pressure management in adults with type 2 diabetes: Insights from the Diabetes Mellitus Status in Canada (DM-SCAN) Survey"], ["AG Holst", 2018, "SUSTAIN 6: Effekt von Semaglutid auf kardiovaskul\u00e4re Endpunkte im zeitlichen Verlauf bei Patienten mit Typ 2 Diabetes (Post-hoc Auswertung)"], ["E J\u00f3dar", 2018, "SUSTAIN 6: Effekt von Semaglutid auf kardiovaskul\u00e4re Endpunkte im zeitlichen Verlauf bei Patienten mit Typ 2 Diabetes (Post-hoc Auswertung)"], ["G Charpentier", 2018, "Semaglutid reduzierte das K\u00f6rpergewicht in den Studien SUSTAIN 1\u20135 unabh\u00e4ngig vom Baseline-BMI"], ["ML Warren", 2018, "Semaglutid reduzierte das K\u00f6rpergewicht in den Studien SUSTAIN 1\u20135 unabh\u00e4ngig vom Baseline-BMI"], ["WT Garwey", 2018, "Semaglutid reduzierte das K\u00f6rpergewicht in den Studien SUSTAIN 1\u20135 unabh\u00e4ngig vom Baseline-BMI"], ["L Masmiquel", 2018, "Semaglutid reduzierte das K\u00f6rpergewicht in den Studien SUSTAIN 1\u20135 unabh\u00e4ngig vom Baseline-BMI"], ["J L\u00fcdemann", 2018, "Semaglutid reduzierte das K\u00f6rpergewicht in den Studien SUSTAIN 1\u20135 unabh\u00e4ngig vom Baseline-BMI"], ["JD Karsb\u00f8l", 2018, "Semaglutid reduzierte das K\u00f6rpergewicht in den Studien SUSTAIN 1\u20135 unabh\u00e4ngig vom Baseline-BMI"], ["L Chaykin", 2018, "Semaglutid reduzierte das K\u00f6rpergewicht in den Studien SUSTAIN 1\u20135 unabh\u00e4ngig vom Baseline-BMI"], ["D Thielke", 2018, "Semaglutid reduzierte das K\u00f6rpergewicht in den Studien SUSTAIN 1\u20135 unabh\u00e4ngig vom Baseline-BMI"], ["PA Johansson", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["SD Wiviott", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["IAM Gausse-Nilsson", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["MS Sabatine", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["MP Bonaca", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["MG Silverman", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["I Raz", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["ET Kato", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["AM Langkilde", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["B St\u00fcrzenhofecker", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["O Mosenzon", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["A Cahn", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["JP Wilding", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["DK McGuire", 2018, "Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation"], ["Rafael Sim\u00f3", 2018, "Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy"], ["Nelun Wijayasinghe", 2018, "Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy"], ["Michael Larsen", 2018, "Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy"], ["Ida Car\u00f8e Helmark", 2018, "Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy"], ["Tina Vilsb\u00f8ll", 2018, "Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy"], ["C Wang", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["M Gerber", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["CH Cabell", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["BL Strom", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Centers for Medicare and Medicaid Services", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Monik C Jim\u00e9nez", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["T Gardner", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["JA Spertus", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Sarah D de Ferranti", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["RM Robertson", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Daniel Lackland", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Martin O\u2019Flaherty", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["V Roger", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["RS Baltimore", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Simin Liu", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Suzanne E Judd", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Lori Chaffin Jordan", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["DC Goff", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["LH Schwamm", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Stephanie E Chiuve", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["K Zhang", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Heather M Alger", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["LY Tani", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["X Zhao", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Joshua Z Willey", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["JJ Zerwic", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["D Goff", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Ambarish Pandey", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Y Yang", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Jenifer H Voeks", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["DK Arnett", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Cathleen Gillespie", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["ST Shulman", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Mary Cushman", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["A Bolger", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["GC Fonarow", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["MD Sullivan", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["JW Newburger", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Y Cao", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["S Wu", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Z Wang", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["KA Taubert", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["DT Durack", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Paul Muntner", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["M Takahashi", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["David B Matchar", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["LM Baddour", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Khurram Nasir", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["P Sorlie", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Matthew D Ritchey", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Jason S Mackey", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["PB Lockhart", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["MS Lauer", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Lynda Lisabeth", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["P Ferrieri", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["JC Burns", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["W Zhang", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Carlos J Rodriguez", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["RO Bonow", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Rajat Deo", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["CW Yancy", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Mathew J Reeves", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["W Wilson", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["N Zhang", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Sally S Wong", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["A Wang", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Jason HY Wu", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["M Zhu", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["J Li", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["John T Wilkins", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["D Treat-Jacobson", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Y Zhang", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Latha P Palaniappan", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["T Pallasch", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["M Gewitz", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["AH Rowley", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Carmen R Isasi", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["M Levison", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["GF Romanelli", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Dilip K Pandey", 2018, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Anders Olsson", 2018, "HDL PARTICLE CONCENTRATION IS NOT ASSOCIATED WITH RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROMES"], ["Prediman Shah", 2018, "HDL PARTICLE CONCENTRATION IS NOT ASSOCIATED WITH RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROMES"], ["Philip Barter", 2018, "HDL PARTICLE CONCENTRATION IS NOT ASSOCIATED WITH RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROMES"], ["John Kittleson", 2018, "HDL PARTICLE CONCENTRATION IS NOT ASSOCIATED WITH RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROMES"], ["Gregory Schwartz", 2018, "HDL PARTICLE CONCENTRATION IS NOT ASSOCIATED WITH RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROMES"], ["Jean Claude Tardif", 2018, "HDL PARTICLE CONCENTRATION IS NOT ASSOCIATED WITH RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROMES"], ["Stephen Nicholls", 2018, "HDL PARTICLE CONCENTRATION IS NOT ASSOCIATED WITH RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROMES"], ["Christie Ballantyne", 2018, "HDL PARTICLE CONCENTRATION IS NOT ASSOCIATED WITH RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROMES"], ["Marc Sabatine", 2018, "RESIDUAL INFLAMMATORY AND CHOLESTEROL RISK IN THE FOURIER TRIAL"], ["Robert Giugliano", 2018, "RESIDUAL INFLAMMATORY AND CHOLESTEROL RISK IN THE FOURIER TRIAL"], ["Terje Pedersen", 2018, "RESIDUAL INFLAMMATORY AND CHOLESTEROL RISK IN THE FOURIER TRIAL"], ["Peter Sever", 2018, "RESIDUAL INFLAMMATORY AND CHOLESTEROL RISK IN THE FOURIER TRIAL"], ["Sabina Murphy", 2018, "RESIDUAL INFLAMMATORY AND CHOLESTEROL RISK IN THE FOURIER TRIAL"], ["Erin Ann Bohula", 2018, "RESIDUAL INFLAMMATORY AND CHOLESTEROL RISK IN THE FOURIER TRIAL"], ["Laura Chiavaroli", 2018, "Effect of pasta in the context of low-glycaemic index dietary patterns on body weight and markers of adiposity: a systematic review and meta-analysis of randomised controlled \u2026"], ["Philip R Schauer", 2018, "Metabolic surgery: weight loss, diabetes, and beyond"], ["Francesco Rubino", 2018, "Metabolic surgery: weight loss, diabetes, and beyond"], ["Lee M Kaplan", 2018, "Metabolic surgery: weight loss, diabetes, and beyond"], ["Manan Pareek", 2018, "Metabolic surgery: weight loss, diabetes, and beyond"], ["Nahal Nasseri", 2018, "Insights into the current management of older adults with type 2 diabetes in the Ontario primary care setting"], ["Lori D Berard", 2018, "Insights into the current management of older adults with type 2 diabetes in the Ontario primary care setting"], ["Jean-Fran\u00e7ois Yale", 2018, "Insights into the current management of older adults with type 2 diabetes in the Ontario primary care setting"], ["Lianne Goldin", 2018, "Insights into the current management of older adults with type 2 diabetes in the Ontario primary care setting"], ["Jean-Fran\u00e7ois Richard", 2018, "Insights into the current management of older adults with type 2 diabetes in the Ontario primary care setting"], ["Lori MacCallum", 2018, "Insights into the current management of older adults with type 2 diabetes in the Ontario primary care setting"], ["Graydon S Meneilly", 2018, "Insights into the current management of older adults with type 2 diabetes in the Ontario primary care setting"], ["Esteban J\u00f3dar Gimeno", 2018, "SUSTAIN 6: Effekt von Semaglutid auf kardiovaskul\u00e4re Endpunkte im zeitlichen Verlauf bei Patienten mit Typ 2 Diabetes (Post-hoc Auswertung)"], ["Lars Holm Damgaard", 2018, "SUSTAIN 6: Effekt von Semaglutid auf kardiovaskul\u00e4re Endpunkte im zeitlichen Verlauf bei Patienten mit Typ 2 Diabetes (Post-hoc Auswertung)"], ["Jochen Seufert", 2018, "SUSTAIN 6: Effekt von Semaglutid auf kardiovaskul\u00e4re Endpunkte im zeitlichen Verlauf bei Patienten mit Typ 2 Diabetes (Post-hoc Auswertung)"], ["Darren K Mcguire", 2018, "Articles Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"], ["John JV Mcmurray", 2018, "Articles Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"], ["Jay S Skyler", 2018, "Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Ref lections From a Diabetes Care Editors\u2019 Expert Forum"], ["Ingrid AM Gause-nilsson", 2018, "The design and rationale for the Dapagli fl ozin Effect on Cardiovascular"], ["Timi Trial", 2018, "The design and rationale for the Dapagli fl ozin Effect on Cardiovascular"], ["Anna Maria", 2018, "The design and rationale for the Dapagli fl ozin Effect on Cardiovascular"], ["A Lira Pineda", 2018, "Ridurre il colesterolo LDL e ridurre l\u2019infiammazione: risultati dai trials con anticorpi monoclonali anti-PCSK9"], ["PS Sever", 2018, "Ridurre il colesterolo LDL e ridurre l\u2019infiammazione: risultati dai trials con anticorpi monoclonali anti-PCSK9"], ["JG Park", 2018, "Ridurre il colesterolo LDL e ridurre l\u2019infiammazione: risultati dai trials con anticorpi monoclonali anti-PCSK9"], ["TR Pedersen", 2018, "Ridurre il colesterolo LDL e ridurre l\u2019infiammazione: risultati dai trials con anticorpi monoclonali anti-PCSK9"], ["EA Bohula", 2018, "Ridurre il colesterolo LDL e ridurre l\u2019infiammazione: risultati dai trials con anticorpi monoclonali anti-PCSK9"], ["H Wang", 2018, "Ridurre il colesterolo LDL e ridurre l\u2019infiammazione: risultati dai trials con anticorpi monoclonali anti-PCSK9"], ["A Keech", 2018, "Ridurre il colesterolo LDL e ridurre l\u2019infiammazione: risultati dai trials con anticorpi monoclonali anti-PCSK9"], ["SA Murphy", 2018, "Ridurre il colesterolo LDL e ridurre l\u2019infiammazione: risultati dai trials con anticorpi monoclonali anti-PCSK9"], ["RP Giugliano", 2018, "Ridurre il colesterolo LDL e ridurre l\u2019infiammazione: risultati dai trials con anticorpi monoclonali anti-PCSK9"], ["N Honarpour", 2018, "Ridurre il colesterolo LDL e ridurre l\u2019infiammazione: risultati dai trials con anticorpi monoclonali anti-PCSK9"], ["Bue Agner", 2018, "Patients with type 2 diabetes on the maximum dose of insulin degludec/liraglutide (IDegLira) achieve glycaemic target: analyses from the DUAL programme"], ["Sanjay Kaul", 2018, "Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors\u2019 expert forum"], ["Julio Rosenstock", 2018, "Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors\u2019 expert forum"], ["William T Cefalu", 2018, "Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors\u2019 expert forum"], ["D M\u00fcller\u2010Wieland", 2018, "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials"], ["MT Baccara\u2010Dinet", 2018, "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials"], ["B Cariou", 2018, "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials"], ["Theodora Temelkova\u2010Kurktschiev", 2018, "Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular \u2026"], ["Denis Xavier", 2018, "Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular \u2026"], ["Wayne H\u2010H Sheu", 2018, "Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular \u2026"], ["Ernesto G Cardona\u2010Munoz", 2018, "Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular \u2026"], ["Jonathan Shaw", 2018, "Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular \u2026"], ["Valdis Pirags", 2018, "Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular \u2026"], ["Prem Pais", 2018, "Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular \u2026"], ["REWIND Trial Investigators", 2018, "Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular \u2026"], ["Charles M Atisso", 2018, "Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular \u2026"], ["Shaun Holt", 2018, "Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular \u2026"], ["Edward Franek", 2018, "Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular \u2026"], ["Namsik Chung", 2018, "Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular \u2026"], ["Lyubov Lytvyn", 2017, "Effect of Plant Protein on Blood Lipids: A Systematic Review and Meta\u2010Analysis of Randomized Controlled Trials"], ["Siying S Li", 2017, "Effect of Plant Protein on Blood Lipids: A Systematic Review and Meta\u2010Analysis of Randomized Controlled Trials"], ["Sarah E Stewart", 2017, "Effect of Plant Protein on Blood Lipids: A Systematic Review and Meta\u2010Analysis of Randomized Controlled Trials"], ["Basil S Lewis", 2017, "Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset \u2026"], ["Gaetano M De Ferrari", 2017, "Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset \u2026"], ["Yehuda Handelsman", 2017, "Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset \u2026"], ["Prakash Deedwania", 2017, "Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset \u2026"], ["Ioanna Gouni-Berthold", 2017, "Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset \u2026"], ["Lisa Aurand", 2017, "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high \u2026"], ["Jaman Maroni", 2017, "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high \u2026"], ["Melanie J Davies", 2017, "Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan\u2010O trial testing a titratable fixed\u2010ratio combination of \u2026"], ["Elisabeth Niemoeller", 2017, "Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan\u2010O trial testing a titratable fixed\u2010ratio combination of \u2026"], ["George Grunberger", 2017, "Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan\u2010O trial testing a titratable fixed\u2010ratio combination of \u2026"], ["Christine Yu", 2017, "Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan\u2010O trial testing a titratable fixed\u2010ratio combination of \u2026"], ["Elisabeth Souhami", 2017, "Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan\u2010O trial testing a titratable fixed\u2010ratio combination of \u2026"], ["F Javier Ampudia\u2010Blasco", 2017, "Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan\u2010O trial testing a titratable fixed\u2010ratio combination of \u2026"], ["John J McMurray", 2017, "Alkaline Phosphatase: An Alternative Inflammatory Risk Marker After Coronary Syndrome"], ["Giulio Marchesini", 2017, "Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment"], ["Juan M Arteaga", 2017, "Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment"], ["Ricardo G\u00f3mez\u2010Huelgas", 2017, "Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment"], ["Elena Nikonova", 2017, "Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment"], ["David Kerr", 2017, "SESSION 3: INNOVATING BEYOND GLUCOSE CONTROL IN DIABETES CARE"], ["Elizabeth Seaquist", 2017, "SESSION 3: INNOVATING BEYOND GLUCOSE CONTROL IN DIABETES CARE"], ["Anne Peters", 2017, "SESSION 3: INNOVATING BEYOND GLUCOSE CONTROL IN DIABETES CARE"], ["Boris Kovatchev", 2017, "SESSION 3: INNOVATING BEYOND GLUCOSE CONTROL IN DIABETES CARE"], ["Thomas Danne", 2017, "SESSION 3: INNOVATING BEYOND GLUCOSE CONTROL IN DIABETES CARE"], ["Timothy Garvey", 2017, "Semaglutide reduces body weight across baseline BMI subgroups across SUSTAIN 1\u20135"], ["Mark Warren", 2017, "Semaglutide reduces body weight across baseline BMI subgroups across SUSTAIN 1\u20135"], ["Desiree Thielke", 2017, "Semaglutide reduces body weight across baseline BMI subgroups across SUSTAIN 1\u20135"], ["Luis Masmiquel", 2017, "Semaglutide reduces body weight across baseline BMI subgroups across SUSTAIN 1\u20135"], ["Louis Chaykin", 2017, "Semaglutide reduces body weight across baseline BMI subgroups across SUSTAIN 1\u20135"], ["Julie Karsbol", 2017, "Semaglutide reduces body weight across baseline BMI subgroups across SUSTAIN 1\u20135"], ["L Damgaard", 2017, "SUSTAIN 6: A POST-HOC ANALYSIS OF THE EFFECT OF SEMAGLUTIDE ON CARDIOVASCULAR OUTCOMES OVER TIME IN SUBJECTS WITH TYPE 2 DIABETES"], ["R Pratley", 2017, "RISK OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES WITH AND WITHOUT PRIOR CARDIOVASCULAR EVENTS: RESULTS FROM THE LEADER TRIAL"], ["N Poulter", 2017, "RISK OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES WITH AND WITHOUT PRIOR CARDIOVASCULAR EVENTS: RESULTS FROM THE LEADER TRIAL"], ["D \u00d8rsted", 2017, "RISK OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES WITH AND WITHOUT PRIOR CARDIOVASCULAR EVENTS: RESULTS FROM THE LEADER TRIAL"], ["T Monk-Hansen", 2017, "RISK OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES WITH AND WITHOUT PRIOR CARDIOVASCULAR EVENTS: RESULTS FROM THE LEADER TRIAL"], ["J Stone", 2017, "GUIDELINES ORIENTED APPROACH TO LIPID (GOAL) MEDICAL PRACTICE ACTIVITY (MPA) TO ACHIEVE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGETS"], ["KK Ray", 2017, "Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM\u2013INSULIN trial"], ["G Bigot", 2017, "Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM\u2013INSULIN trial"], ["RR Henry", 2017, "Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM\u2013INSULIN trial"], ["L Aurand", 2017, "Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM\u2013INSULIN trial"], ["M Bujas-Bobanovic", 2017, "Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM\u2013INSULIN trial"], ["J Maroni", 2017, "Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM\u2013INSULIN trial"], ["D M\u00fcller-Wieland", 2017, "Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM\u2013INSULIN trial"], ["HM Colhoun", 2017, "Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM\u2013INSULIN trial"], ["Erik Christiansen", 2017, "Severe Hypoglycemia, Cardiovascular Outcomes and Death in LEADER"], ["Salvatore Calanna", 2017, "Severe Hypoglycemia, Cardiovascular Outcomes and Death in LEADER"], ["Steven Marso", 2017, "Severe Hypoglycemia, Cardiovascular Outcomes and Death in LEADER"], ["Jean-Marie Eko\u00e9", 2017, "Type 2 Diabetes (T2D) Management in Primary Care: Still Room for Improvement"], ["Stewart B Harris", 2017, "Type 2 Diabetes (T2D) Management in Primary Care: Still Room for Improvement"], ["Irene M Hramiak", 2017, "Type 2 Diabetes (T2D) Management in Primary Care: Still Room for Improvement"], ["WT Garvey", 2017, "\u00c9tudes SUSTAIN 1-5: perte de poids sous semaglutide selon la cat\u00e9gorie d\u2019IMC initial"], ["A Bouzidi", 2017, "\u00c9tudes SUSTAIN 1-5: perte de poids sous semaglutide selon la cat\u00e9gorie d\u2019IMC initial"], ["B Verg\u00e8s", 2017, "SUSTAIN 6: analyse post-hoc de la survenue des \u00e9v\u00e9nements cardiovasculaires majeurs au cours des 2 ans de suivi"], ["A Langkilde", 2017, "Baseline characteristics of the DECLARE-TIMI 58 trial population"], ["IAM Gause-Nilsson", 2017, "Baseline characteristics of the DECLARE-TIMI 58 trial population"], ["E Jaeckel", 2017, "Insulin degludec/liraglutide (IDegLira) provides clinical benefits across all end of trial dose ranges: analyses from DUAL I and V"], ["JN Harvey", 2017, "Insulin degludec/liraglutide (IDegLira) provides clinical benefits across all end of trial dose ranges: analyses from DUAL I and V"], ["LF Meneghini", 2017, "Insulin degludec/liraglutide (IDegLira) provides clinical benefits across all end of trial dose ranges: analyses from DUAL I and V"], ["I Lingvay", 2017, "Insulin degludec/liraglutide (IDegLira) provides clinical benefits across all end of trial dose ranges: analyses from DUAL I and V"], ["K Begtrup", 2017, "Insulin degludec/liraglutide (IDegLira) provides clinical benefits across all end of trial dose ranges: analyses from DUAL I and V"], ["IH Langbakke", 2017, "Insulin degludec/liraglutide (IDegLira) provides clinical benefits across all end of trial dose ranges: analyses from DUAL I and V"], ["T Vilsboll", 2017, "Insulin degludec/liraglutide (IDegLira) provides clinical benefits across all end of trial dose ranges: analyses from DUAL I and V"], ["K Chandarana", 2017, "\u00c9tude DUAL V: l\u2019efficacit\u00e9 d\u2019IDegLira est ind\u00e9pendante de la dose d\u2019insuline glargine administr\u00e9e avant l\u2019\u00e9tude"], ["T Vilsbol", 2017, "\u00c9tude DUAL V: l\u2019efficacit\u00e9 d\u2019IDegLira est ind\u00e9pendante de la dose d\u2019insuline glargine administr\u00e9e avant l\u2019\u00e9tude"], ["N Chevalier", 2017, "\u00c9tude DUAL V: l\u2019efficacit\u00e9 d\u2019IDegLira est ind\u00e9pendante de la dose d\u2019insuline glargine administr\u00e9e avant l\u2019\u00e9tude"], ["L Meneghini", 2017, "\u00c9tude DUAL V: l\u2019efficacit\u00e9 d\u2019IDegLira est ind\u00e9pendante de la dose d\u2019insuline glargine administr\u00e9e avant l\u2019\u00e9tude"], ["J Harvey", 2017, "\u00c9tude DUAL V: l\u2019efficacit\u00e9 d\u2019IDegLira est ind\u00e9pendante de la dose d\u2019insuline glargine administr\u00e9e avant l\u2019\u00e9tude"], ["J List", 2017, "Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes"], ["U Vijapurkar", 2017, "Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes"], ["MJ Davies", 2017, "Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes"], ["R Cuddihy", 2017, "Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes"], ["J Ren", 2017, "Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes"], ["J Thurman", 2017, "IDegLira am\u00e9liore les marqueurs de risque cardiovasculaire chez les diab\u00e9tiques de type 2 (DT2) insuffisamment contr\u00f4l\u00e9s sous insuline basale: analyses de DUAL II et DUAL V"], ["B Agner", 2017, "IDegLira am\u00e9liore les marqueurs de risque cardiovasculaire chez les diab\u00e9tiques de type 2 (DT2) insuffisamment contr\u00f4l\u00e9s sous insuline basale: analyses de DUAL II et DUAL V"], ["L Lehmann", 2017, "IDegLira am\u00e9liore les marqueurs de risque cardiovasculaire chez les diab\u00e9tiques de type 2 (DT2) insuffisamment contr\u00f4l\u00e9s sous insuline basale: analyses de DUAL II et DUAL V"], ["T Belvins", 2017, "IDegLira am\u00e9liore les marqueurs de risque cardiovasculaire chez les diab\u00e9tiques de type 2 (DT2) insuffisamment contr\u00f4l\u00e9s sous insuline basale: analyses de DUAL II et DUAL V"], ["B Bode", 2017, "IDegLira am\u00e9liore les marqueurs de risque cardiovasculaire chez les diab\u00e9tiques de type 2 (DT2) insuffisamment contr\u00f4l\u00e9s sous insuline basale: analyses de DUAL II et DUAL V"], ["E Disse", 2017, "IDegLira am\u00e9liore les marqueurs de risque cardiovasculaire chez les diab\u00e9tiques de type 2 (DT2) insuffisamment contr\u00f4l\u00e9s sous insuline basale: analyses de DUAL II et DUAL V"], ["Neil Poulter", 2017, "IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUALV"], ["Elmar Jaeckel", 2017, "IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUALV"], ["BW Bode", 2017, "IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUALV"], ["Lucine Lehmann", 2017, "IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUALV"], ["Jerry Thurman", 2017, "IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUALV"], ["Bue F Ross Agner", 2017, "IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUALV"], ["T Blevins", 2017, "IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUALV"], ["Tina Vilsboll", 2017, "IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUALV"], ["Sanjay Rajagopalan", 2017, "Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment\u2013a clinical appraisal"], ["Jiten Vora", 2017, "Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment\u2013a clinical appraisal"], ["Kausik Ray", 2017, "Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment\u2013a clinical appraisal"], ["Laurence Bessac", 2017, "Alirocumab treatment and achievement of non\u2010high\u2010density lipoprotein cholesterol and apolipoprotein b goals in patients with hypercholesterolemia: pooled results from 10 phase \u2026"], ["Robert Pordy", 2017, "Alirocumab treatment and achievement of non\u2010high\u2010density lipoprotein cholesterol and apolipoprotein b goals in patients with hypercholesterolemia: pooled results from 10 phase \u2026"], ["Peter P Toth", 2017, "Alirocumab treatment and achievement of non\u2010high\u2010density lipoprotein cholesterol and apolipoprotein b goals in patients with hypercholesterolemia: pooled results from 10 phase \u2026"], ["Diane Miller", 2017, "Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: results over 52 weeks"], ["HARMONY 6 Study Group", 2017, "Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: results over 52 weeks"], ["Jorge Luiz Gross", 2017, "Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: results over 52 weeks"], ["Francis Chow", 2017, "Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: results over 52 weeks"], ["Susan Johnson", 2017, "Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: results over 52 weeks"], ["Alice Cheng", 2017, "A practical guide to the use of glucose-lowering agents with cardiovascular benefit or proven safety"], ["Jos\u00e9 Luis Zamorano", 2017, "Lipid\u2010lowering efficacy and safety of alirocumab in patients with or without diabetes: a sub\u2010analysis of ODYSSEY COMBO II"], ["Christopher P Cannon", 2017, "Lipid\u2010lowering efficacy and safety of alirocumab in patients with or without diabetes: a sub\u2010analysis of ODYSSEY COMBO II"], ["Guillaume Lecorps", 2017, "Lipid\u2010lowering efficacy and safety of alirocumab in patients with or without diabetes: a sub\u2010analysis of ODYSSEY COMBO II"], ["Luigi F Meneghini", 2017, "Insulin Degludec/Liraglutide (IDegLira) Provides Clinical Benefits across All End of Trial (EOT) Dose Ranges: Analyses from DUAL I and V"], ["Kamilla Begtrup", 2017, "Insulin Degludec/Liraglutide (IDegLira) Provides Clinical Benefits across All End of Trial (EOT) Dose Ranges: Analyses from DUAL I and V"], ["John N Harvey", 2017, "Insulin Degludec/Liraglutide (IDegLira) Provides Clinical Benefits across All End of Trial (EOT) Dose Ranges: Analyses from DUAL I and V"], ["Irene H Langbakke", 2017, "Insulin Degludec/Liraglutide (IDegLira) Provides Clinical Benefits across All End of Trial (EOT) Dose Ranges: Analyses from DUAL I and V"], ["Keval Chandarana", 2017, "Converting to insulin degludec/liraglutide (IDegLira) is efficacious regardless of pretrial insulin dose in patients with type 2 diabetes (T2D) uncontrolled on insulin glargine \u2026"], ["Christine S Tsilas", 2017, "Relation of total sugars, fructose and sucrose with incident type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies"], ["Reem Tawfik", 2017, "Relation of total sugars, fructose and sucrose with incident type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies"], ["Marco Di Buono", 2017, "Relation of total sugars, fructose and sucrose with incident type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies"], ["Viranda H Jayalath", 2017, "Relation of total sugars, fructose and sucrose with incident type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies"], ["Arash Mirrahimi", 2017, "Relation of total sugars, fructose and sucrose with incident type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies"], ["Alexandra L Jenkins", 2017, "Relation of total sugars, fructose and sucrose with incident type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies"], ["Joseph Beyene", 2017, "Relation of total sugars, fructose and sucrose with incident type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies"], ["Hoang Vi Thanh Ho", 2017, "A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets \u2026"], ["Lea Duvnjak", 2017, "A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets \u2026"], ["Fei Au-Yeung", 2017, "A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets \u2026"], ["Andreea Zurbau", 2017, "A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets \u2026"], ["Elena Jovanovski", 2017, "A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets \u2026"], ["Linong Ji", 2017, "Gaps and barriers in the control of blood glucose in people with type 2 diabetes"], ["Lawrence Blonde", 2017, "Gaps and barriers in the control of blood glucose in people with type 2 diabetes"], ["Pablo Aschner", 2017, "Gaps and barriers in the control of blood glucose in people with type 2 diabetes"], ["Clifford Bailey", 2017, "Gaps and barriers in the control of blood glucose in people with type 2 diabetes"], ["Stephan Matthaei", 2017, "Gaps and barriers in the control of blood glucose in people with type 2 diabetes"], ["Global Partnership for Effective Diabetes Management", 2017, "Gaps and barriers in the control of blood glucose in people with type 2 diabetes"], ["Shelagh B Coutts", 2017, "Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults"], ["Mukul Sharma", 2017, "Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults"], ["Thomas W Wilson", 2017, "Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults"], ["Debra Reid", 2017, "Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults"], ["Ally Prebtani", 2017, "Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults"], ["Denis Drouin", 2017, "Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults"], ["Gregory Moullec", 2017, "Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults"], ["Kevin D Burns", 2017, "Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults"], ["Kara Nerenberg", 2017, "Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults"], ["Jean-Martin Boulanger", 2017, "Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults"], ["Scott A Lear", 2017, "Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults"], ["Milan Khara", 2017, "Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults"], ["Roland PT Troquay", 2017, "Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol"], ["Frank LJ Visseren", 2017, "Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol"], ["Robert Dufour", 2017, "Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol"], ["Mahir Karakas", 2017, "Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol"], ["Traci Turner", 2017, "Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol"], ["Tim Hall", 2017, "Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol"], ["MD Lawrence Leiter", 2017, "Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes mellitus"], ["Richard Grimm", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["Faramarz Ismail-Beigi", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["David C Goff", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["Marshall B Elam", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["Mary Ellen Sweeney", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["Laura C Lovato", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["William T Friedewald", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["Carlos Lopez", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["Daniel Weiss", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["Robert P Byington", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["Marshall Corson", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["Patrick J O\u2019Connor", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["Jerome L Fleg", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["Joseph Largay", 2017, "Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes"], ["Thomas M Wolever", 2017, "\u201cCatalytic\u201d Doses of Fructose and its Epimers on Glycemic Control: A Systematic Review and Meta-Analysis of Controlled Feeding Trials"], ["Andrea Glenn", 2017, "\u201cCatalytic\u201d Doses of Fructose and its Epimers on Glycemic Control: A Systematic Review and Meta-Analysis of Controlled Feeding Trials"], ["Catherine Braunstein", 2017, "\u201cCatalytic\u201d Doses of Fructose and its Epimers on Glycemic Control: A Systematic Review and Meta-Analysis of Controlled Feeding Trials"], ["N Wilson Rodger", 2017, "Effects of changing the amount and source of dietary carbohydrates on symptoms and dietary satisfaction over a 1-year period in subjects with type 2 diabetes: Canadian Trial of \u2026"], ["Jean-Louis Chiasson", 2017, "Effects of changing the amount and source of dietary carbohydrates on symptoms and dietary satisfaction over a 1-year period in subjects with type 2 diabetes: Canadian Trial of \u2026"], ["Edmond A Ryan", 2017, "Effects of changing the amount and source of dietary carbohydrates on symptoms and dietary satisfaction over a 1-year period in subjects with type 2 diabetes: Canadian Trial of \u2026"], ["Pierre Maheux", 2017, "Effects of changing the amount and source of dietary carbohydrates on symptoms and dietary satisfaction over a 1-year period in subjects with type 2 diabetes: Canadian Trial of \u2026"], ["R\u00e9mi Rabasa-Lhoret", 2017, "Effects of changing the amount and source of dietary carbohydrates on symptoms and dietary satisfaction over a 1-year period in subjects with type 2 diabetes: Canadian Trial of \u2026"], ["Robert G Josse", 2017, "Effects of changing the amount and source of dietary carbohydrates on symptoms and dietary satisfaction over a 1-year period in subjects with type 2 diabetes: Canadian Trial of \u2026"], ["Tim Garvey", 2017, "EFFECTS OF CANAGLIFLOZIN VERSUS GLIMEPIRIDE ON INFLAMMATORY BIOMARKERS AND CHEMOKINES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS"], ["Michael Davies", 2017, "EFFECTS OF CANAGLIFLOZIN VERSUS GLIMEPIRIDE ON INFLAMMATORY BIOMARKERS AND CHEMOKINES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS"], ["Peter Jones", 2017, "Alirocumab safety in individuals with and without diabetes mellitus: pooled data from 14 ODYSSEY trials"], ["Dean Karalis", 2017, "Alirocumab safety in individuals with and without diabetes mellitus: pooled data from 14 ODYSSEY trials"], ["D Lackland", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["K Matsushita", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["RW Neumar", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["JZ Willey", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["L Lisabeth", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["SE Judd", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["GA Roth", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["Michael J Blaha", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["Sandeep R Das", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["MJ Reeves", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["DK Pandey", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["MB Turner", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["CR Isasi", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["M Ritchey", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["A Towfighi", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["C Sasson", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["JH Wu", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["JH Voeks", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["M Fornage", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["LC Jordan", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["J Floyd", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["S Liu", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["C Gillespie", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["RR Thiagarajan", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["HM Alger", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["ME Mussolino", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["RH Mackey", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["K Nasir", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["CT Longenecker", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["L Palaniappan", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["JT Wilkins", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["JH Lichtman", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["P Muntner", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["SS Wong", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["CJ Rodriguez", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["CW Tsao", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["SS Virani", 2017, "Heart disease and stroke statistics-2017 update: a report from the American Heart Association."], ["Sathish Chandra Pichika", 2017, "Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial"], ["Russell J De Souza", 2017, "Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial"], ["Alan R Moody", 2017, "Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial"], ["Balachandran Bashyam", 2017, "Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial"], ["Omodele Olowoyeye", 2017, "Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial"], ["Livia SA Augustin", 2017, "Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial"], ["Darshna Patel", 2017, "Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial"], ["Christopher Ireland", 2017, "Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial"], ["Sandhya Sahye-Pudaruth", 2017, "Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial"], ["Gail E McKeown-Eyssen", 2017, "Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial"], ["Judy Coveney", 2017, "Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial"], ["Stephanie K Nishi", 2017, "Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial"], ["Sandra Mitchell", 2017, "Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial"], ["Jean\u2010Claude Tardif", 2017, "Aldosterone does not predict cardiovascular events following acute coronary syndrome in patients initially without heart failure"], ["Reynaria Pitts", 2017, "Aldosterone does not predict cardiovascular events following acute coronary syndrome in patients initially without heart failure"], ["Elise Gunzburger", 2017, "Aldosterone does not predict cardiovascular events following acute coronary syndrome in patients initially without heart failure"], ["Ym Cho", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["S De Cosmo", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["A Al-Karadsheh", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["R Alappan", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["M Burgos Soto", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["V Andreeva", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["S Antic", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["D Coyne", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["E Davies", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Y Canaan", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["D Cosma", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["A Dawson", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["N Chen", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Rs Comia", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["O Barysheva", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Accini Mendoza JL", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["H Aoki", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["J Baker", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Am Cusumano", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["D Dev", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["L De Nicola", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["S Davies", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["R Bentley-Lewis", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["J Baas Cruz", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["E de Souza Portes", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["P Alvarez Garcia", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["P Castellino", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["A Asano", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["O Benusova", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["N Aggarwal", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["D Aizenberg", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["O Brusco", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["C Chuateco", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["K Cohen", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["V Arutchelvam", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["O Abraham", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["K Abdul Kadir", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["D Brandon", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Ap Bordonava", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["D Bartaskova", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["A Chew Wong", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["C Bowman-Stroud", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["R Cohen", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Q Chen", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Z Ali", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["C Amodeo", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Lr Cartasegna", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["G Bakris", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["S De Serres", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["C Christiano", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["J Abdallah", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["R Busch", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["E Alamartine", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["V Commendatore", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["J Chevaile Ramos", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["M Dhillon", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["N Daboul", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["F Ahmed", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["R Alicic", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Ma Berli", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["S Cigarran Guldris", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["M Alpizar Salazar", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["E Arce-Nunez", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Andreotti Turatti LA", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["O Barna", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["V Behara", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["T Chang", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["C Crisan", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Ar Chacra", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Lm Chuang", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["A Cif", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Nw Cheung", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Lh Canani", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["G Daroza", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["S Cournoyer", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Camelo Sanches FC", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["M Bernardo", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["G Csecsei", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["H Akiyama", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["A Badat", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["D Chizhov", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["A Arif", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["D Deepak", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["I Buganova", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["G Certow", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["A Akyea-Djamson", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["P Ainsworth", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["M Davies", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["I Bartolacci", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["G Aquitania", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Cunha Borges JL", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Che Yusof", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["E Christofides", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["R Abdul Ghani", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["N Atray", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["A Alvarisqueta", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["J Aiello", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["P Calella", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Dw Chae", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["L Akright", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["C Arauz-Pacheco", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["R Berenguer", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Cunha V\u00eancio SA", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["A Awad", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["A Agafyina", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["V Anghel", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["F Cereto Castro", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["S Borot", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["D Cherney", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["L Deak", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["V Botsyurko", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["J Cuadrado", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["S Abusnana", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["J Babikova", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["C Cook", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["I Acosta", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["J Conway", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Arcos Palma EG", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["RJ da Silva Franco", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["N Ali", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Ahuad Guerrero RA", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Gc Coloma", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["C Barrera", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Mm Busegeanu", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["S Arfeen", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["E Barranco", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["R Bregman", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["B Csiky", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Lm Angelescu", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["D Belo", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Z Abejuela", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Ri Avram", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Ct Chang", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["L Chiovato", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["K Deck", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["A Angelova", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["R Abdullah", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["G Derosa", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Mc Cantero", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Ca Cuneo", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["M Biscoveanu", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["O Barbarash", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["P Danos", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["M Abramowitz", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["M Barnard", 2017, "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics"], ["Esteban J\u00f3dar", 2017, "SUSTAIN 6: une analyse post-hoc sur la dynamique de survenue d\u2019\u00e9v\u00e9nements cardio-vasculaires majeurs au cours des 2 ans de la p\u00e9riode d\u2019\u00e9tude"], ["Lawrence A Leiter5-Poster NP317", 2017, "SUSTAIN 6: une analyse post-hoc sur la dynamique de survenue d\u2019\u00e9v\u00e9nements cardio-vasculaires majeurs au cours des 2 ans de la p\u00e9riode d\u2019\u00e9tude"], ["Bruno Verg\u00e8s", 2017, "SUSTAIN 6: une analyse post-hoc sur la dynamique de survenue d\u2019\u00e9v\u00e9nements cardio-vasculaires majeurs au cours des 2 ans de la p\u00e9riode d\u2019\u00e9tude"], ["Poulter N NJ", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["MA Cavender", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["R Conwit", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["NR Desai", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["R Frederich", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["PN Peduzzi", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["W Clark", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["JR O\u2019Leary", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["LM Brass", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["PS Pollack", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["HP Adams", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["D Kleindorfer", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["JA Udell", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["A Ramachandran", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["L Berger", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["AA Umez-Eronini", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["BS Lewis", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["Lovejoy AM PD", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["A Carolei", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["EB Hoffman", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["GA Ford", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["K Im", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["GG Schwartz", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["B Coull", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["B Hirshberg", 2017, "Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on \u2026"], ["Thomas C Blevins", 2017, "IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin"], ["International Hypoglycaemia Study Group", 2017, "Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the \u2026"], ["Ildiko Lingway", 2017, "Converting to IDegLira is efficacious regardless of pre-trial insulin dose in patients with type 2 diabetes uncontrolled on insulin glargine U100"], ["Luigi F Meneghino", 2017, "Converting to IDegLira is efficacious regardless of pre-trial insulin dose in patients with type 2 diabetes uncontrolled on insulin glargine U100"], ["Daniel Ngui", 2017, "Cardiology & Cardiovascular Medicine Journal"], ["Jan O Friedrich", 2017, "Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis"], ["J Grenier", 2017, "Blood Pressure Management in Patients with Diabetes: Insights From the Diabetes Mellitus Status in Canada Survey"], ["SG Goodman", 2017, "Blood Pressure Management in Patients with Diabetes: Insights From the Diabetes Mellitus Status in Canada Survey"], ["H Teoh", 2017, "Blood Pressure Management in Patients with Diabetes: Insights From the Diabetes Mellitus Status in Canada Survey"], ["Frank L Visseren", 2016, "Inhibition of PCSK9 synthesis via RNA interference: 90 day data from Orion-1-a Multi-Centre Phase-2 Randomized Controlled Trial"], ["Peter Wijngaarcr", 2016, "Inhibition of PCSK9 synthesis via RNA interference: 90 day data from Orion-1-a Multi-Centre Phase-2 Randomized Controlled Trial"], ["Timothy Hall", 2016, "Inhibition of PCSK9 synthesis via RNA interference: 90 day data from Orion-1-a Multi-Centre Phase-2 Randomized Controlled Trial"], ["Eric J Niesor", 2016, "Treatment with dalcetrapib modifies the relationship between high-density lipoprotein cholesterol and C-reactive protein"], ["M Eriksson", 2016, "LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial"], ["E Franek", 2016, "LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial"], ["S Jacob", 2016, "LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial"], ["A Comlekci", 2016, "LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial"], ["FMM Baeres", 2016, "LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial"], ["J Vidal", 2016, "LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial"], ["L van Gaal", 2016, "LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial"], ["SP Marso", 2016, "LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial"], ["John Petrie", 2016, "LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial"], ["Agostino Consoli", 2016, "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes"], ["Freddy G Eliaschewitz", 2016, "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes"], ["Jonas Pettersson", 2016, "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes"], ["Oluf Hansen", 2016, "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes"], ["Anders G Holst", 2016, "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes"], ["Ruth McPherson", 2016, "2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult"], ["Martin Dawes", 2016, "2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult"], ["Patrick Couture", 2016, "2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult"], ["Gordon A Francis", 2016, "2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult"], ["Todd J Anderson", 2016, "2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult"], ["Richard Ward", 2016, "2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult"], ["George Thanassoulis", 2016, "2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult"], ["Jacques Genest Jr", 2016, "2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult"], ["Arden R Barry", 2016, "2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult"], ["David C Lau", 2016, "2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult"], ["Jennifer G Robinson", 2016, "No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies"], ["Laurence Merlet", 2016, "No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies"], ["Robert H Eckel", 2016, "No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies"], ["MT Baccara-Dinet", 2016, "ALIROCUMAB EFFICACY AND SAFETY IN PATIENTS WITH PRE-DIABETES VERSUS NORMOGLYCEMIA"], ["Lori Maccallum", 2016, "Where Do We Stand with the Management of Older Adults with Type 2 Diabetes in Canadian Primary Care?"], ["Lori Berard", 2016, "Where Do We Stand with the Management of Older Adults with Type 2 Diabetes in Canadian Primary Care?"], ["Jean-Francois Richard", 2016, "Where Do We Stand with the Management of Older Adults with Type 2 Diabetes in Canadian Primary Care?"], ["Sara Rehman", 2016, "Fructose intake and risk of gout and hyperuricemia: a systematic review and meta-analysis of prospective cohort studies"], ["Joseph Jamnik", 2016, "Fructose intake and risk of gout and hyperuricemia: a systematic review and meta-analysis of prospective cohort studies"], ["RR Reinhardt", 2016, "Gastrointestinal safety across the albiglutide development programme"], ["JM Mallory", 2016, "Gastrointestinal safety across the albiglutide development programme"], ["TH Wilson", 2016, "Gastrointestinal safety across the albiglutide development programme"], ["Amit Bhandari", 2016, "Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: analysis of pooled events from 19 clinical trials"], ["Michael Lehrke", 2016, "Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: analysis of pooled events from 19 clinical trials"], ["Thomas Meinicke", 2016, "Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: analysis of pooled events from 19 clinical trials"], ["Sandra Thiemann", 2016, "Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: analysis of pooled events from 19 clinical trials"], ["Uwe Hehnke", 2016, "Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: analysis of pooled events from 19 clinical trials"], ["Odd Erik Johansen", 2016, "Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: analysis of pooled events from 19 clinical trials"], ["K Thompson", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["TC Ooi", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["V Reiding", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["P Kirkland", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["R Buhrmann", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["Y Rosenberg", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["P Pauli", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["Hillary T Graham", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["N Shehadeh", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["C Smith", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["U Kumar", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["T Paul", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["T Valla", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["A Jeffrys", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["M Pick", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["I Hramiak", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["DJ Mitchell", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["C Barbeau", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["AL Edwards", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["J Maranger", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["G Walsh", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["P Mackie", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["C Lincoln", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["V Trinh", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["Daniel M Rotroff", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["Rose Otto", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["P Manjoo", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["P Harvey", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["C Joyce", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["Audrey Moroso", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["J Burton", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["P Gauthier", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["A Davis", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["J Abe", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["T McDonald", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["Z Punthakee", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["R Smart", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["M Labb\u00e9", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["Skylar W Marvel", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["M Gillam", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["M Tennant", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["S Hall", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["R Russo", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["E Ryan", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["S Tereschyn", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["B Murphy", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["V Vasudeva", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["B Hammond", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["A Schiffrin", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["W Zimmerman", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["R Duchesne", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["R Sigal", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["A Stark", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["V Chaudhary", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["I Stanton", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["JL Probstfield", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["M Cyr", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["A B\u00e9langer", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["A Bertoni", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["S Danby", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["Michael J Wagner", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["A Kherani", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["M Parsons", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["D Hartmann", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["Tammy M Havener", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["A Gafni", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["S CoadyMcDonald", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["K Chrysler", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["J Girouard", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["H Jensen", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["DG Simons-Morton", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["S Genuth", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["K Dalton", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["H Lochnan", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["L Bradley", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["B Paty", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["RP Byington", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["W Gendall", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["B Schwanke", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["J Kaszyca", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["Alyson G Wilson", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["M Vallis", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["J Gonder", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["C Kovacs", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["V Chandurkar", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["V Pringle", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["D Weiss-Aburto", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["JT Bigger", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["D Gibbons", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["N Kandalaft", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["T Cukierman-Yaffe", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["D Wright", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["C MacDonald", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["E Lonn", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["N Ronald", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["B Rowe", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["WT Friedewald", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["F Morales", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["W Harper", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["V McCarthy", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["M Driscoll", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["C Gilchrist", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["G Bahsali", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["M Gehring", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["KL Hill", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["S Gauthier", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["RH Grimm Jr", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["C McDonald", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["S Yusuf", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["M Walker", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["MA Clearwaters", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["N Makhani", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["S Anand", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["C Dielissen", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["B Woloschuk", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["L Vancer", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["J Palardy", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["WC Cushman", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["B Cracknell", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["RJ Sigal", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["HN Ginsberg", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["B Tadeson", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["E Caponi", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["A Smith", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["I Wilderman", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["D Hunt", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["G Williams", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["D Lau", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["L Mereu", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["W McBeth", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["S Powers", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["Alison A Motsinger-Reif", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["G Guyatt", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["M Pilon", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["P WerbiskiWood", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["J Germsheid", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["D Rabi", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["JB Buse", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["S Varma", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["F Ismail-Beigi", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["S Capes", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["HC Gerstein", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["S Varghese", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["P Senior", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["S Mawani", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["R Dumas", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["J Raymond", 2016, "Incorporating concomitant medications into genome-wide analyses for the study of complex disease and drug response"], ["M-R Taskinen", 2016, "Relationship between triglyceride-rich lipoprotein cholesterol concentrations and non-RDL cholesterol goal attainment in ODYSSEY phase 3 trials"], ["AJ Vallejo-Vaz", 2016, "Relationship between triglyceride-rich lipoprotein cholesterol concentrations and non-RDL cholesterol goal attainment in ODYSSEY phase 3 trials"], ["D Mueller-Wieland", 2016, "Alirocumab efficacy and safety in patients with pre-diabetes versus normoglycaemia"], ["C Yu", 2016, "Outcomes of LixiLan, a fixed-ratio combination of insulin glargine/lixisenatide, versus insulin glargine and lixisenatide by baseline characteristics: LixiLan-O trial"], ["G Grunberger", 2016, "Outcomes of LixiLan, a fixed-ratio combination of insulin glargine/lixisenatide, versus insulin glargine and lixisenatide by baseline characteristics: LixiLan-O trial"], ["E Souhami", 2016, "Outcomes of LixiLan, a fixed-ratio combination of insulin glargine/lixisenatide, versus insulin glargine and lixisenatide by baseline characteristics: LixiLan-O trial"], ["E Niemoeller", 2016, "Outcomes of LixiLan, a fixed-ratio combination of insulin glargine/lixisenatide, versus insulin glargine and lixisenatide by baseline characteristics: LixiLan-O trial"], ["F Ampudia-Blasco", 2016, "Outcomes of LixiLan, a fixed-ratio combination of insulin glargine/lixisenatide, versus insulin glargine and lixisenatide by baseline characteristics: LixiLan-O trial"], ["B Guerci", 2016, "Outcomes of LixiLan, a fixed-ratio combination of insulin glargine/lixisenatide, versus insulin glargine and lixisenatide by baseline characteristics: LixiLan-O trial"], ["W Stager", 2016, "Outcomes of LixiLan, a fixed-ratio combination of insulin glargine/lixisenatide, versus insulin glargine and lixisenatide by baseline characteristics: LixiLan-O trial"], ["J Rosenstock", 2016, "Outcomes of LixiLan, a fixed-ratio combination of insulin glargine/lixisenatide, versus insulin glargine and lixisenatide by baseline characteristics: LixiLan-O trial"], ["A Acusta", 2016, "Effects of mild to moderate renal impairment on albiglutide (ALBI) in type 2 diabetes"], ["V Bainbridge", 2016, "Effects of mild to moderate renal impairment on albiglutide (ALBI) in type 2 diabetes"], ["B Ahren", 2016, "Effects of mild to moderate renal impairment on albiglutide (ALBI) in type 2 diabetes"], ["A Jones-Leone", 2016, "Effects of mild to moderate renal impairment on albiglutide (ALBI) in type 2 diabetes"], ["TH Andersen", 2016, "Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double\u2010blind randomized controlled \u2026"], ["A Philis\u2010Tsimikas", 2016, "Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double\u2010blind randomized controlled \u2026"], ["J Zacho", 2016, "Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double\u2010blind randomized controlled \u2026"], ["Philip Raskin", 2016, "Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double\u2010blind randomized controlled \u2026"], ["S Kumar", 2016, "Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double\u2010blind randomized controlled \u2026"], ["TS Bailey", 2016, "Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double\u2010blind randomized controlled \u2026"], ["Jean Gregoire", 2016, "Secondary prevention beyond hospital discharge for acute coronary syndrome: evidence-based recommendations"], ["Robert Welsh", 2016, "Secondary prevention beyond hospital discharge for acute coronary syndrome: evidence-based recommendations"], ["Peter Lin", 2016, "Secondary prevention beyond hospital discharge for acute coronary syndrome: evidence-based recommendations"], ["Philip Mcfarlane", 2016, "Secondary prevention beyond hospital discharge for acute coronary syndrome: evidence-based recommendations"], ["Vera A Bittner", 2016, "Effects of extended-release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM-HIGH"], ["John R Guyton", 2016, "Effects of extended-release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM-HIGH"], ["Carol Wysham", 2016, "Effects of extended-release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM-HIGH"], ["Richard L Dunbar", 2016, "Effects of extended-release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM-HIGH"], ["Ping Xu", 2016, "Effects of extended-release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM-HIGH"], ["Ruth McBride", 2016, "Effects of extended-release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM-HIGH"], ["William E Boden", 2016, "Effects of extended-release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM-HIGH"], ["Debra L Simmons", 2016, "Effects of extended-release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM-HIGH"], ["Ronald B Goldberg", 2016, "Effects of extended-release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM-HIGH"], ["Alan R Berger", 2016, "Low-glycaemic index diet to improve glycaemic control and cardiovascular disease in type 2 diabetes: design and methods for a randomised, controlled, clinical trial"], ["Gail McKeown-Eyssen", 2016, "Low-glycaemic index diet to improve glycaemic control and cardiovascular disease in type 2 diabetes: design and methods for a randomised, controlled, clinical trial"], ["Tishan Maraj", 2016, "Low-glycaemic index diet to improve glycaemic control and cardiovascular disease in type 2 diabetes: design and methods for a randomised, controlled, clinical trial"], ["Melanie Davies", 2016, "Impact of Baseline HbA1c, BMI, and Diabetes Duration on the Efficacy and Safety of LixiLan (Insulin Glargine/Lixisenatide Titratable Fixed-Ratio Combination) vs. Insulin \u2026"], ["F Javier Ampudia-Blasco", 2016, "Impact of Baseline HbA1c, BMI, and Diabetes Duration on the Efficacy and Safety of LixiLan (Insulin Glargine/Lixisenatide Titratable Fixed-Ratio Combination) vs. Insulin \u2026"], ["William Canovatchel", 2016, "Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin"], ["Gisle Langslet", 2016, "Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin"], ["Angela Jones-Leone", 2016, "Effects of Mild to Moderate Renal Impairment on Albiglutide (ALBI) in Type 2 Diabetes (T2DM)"], ["Andre Acusta", 2016, "Effects of Mild to Moderate Renal Impairment on Albiglutide (ALBI) in Type 2 Diabetes (T2DM)"], ["Bo Ahren", 2016, "Effects of Mild to Moderate Renal Impairment on Albiglutide (ALBI) in Type 2 Diabetes (T2DM)"], ["Veronica Bain Bridge", 2016, "Effects of Mild to Moderate Renal Impairment on Albiglutide (ALBI) in Type 2 Diabetes (T2DM)"], ["Dirk Mueller-Wieland", 2016, "Alirocumab Efficacy and Safety in Patients with Prediabetes vs. Normoglycemia"], ["Stephan Jacob", 2016, "LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial"], ["Johannes F Mann", 2016, "LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial"], ["John R Petrie", 2016, "LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial"], ["Florian MM Baeres", 2016, "LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial"], ["Mohamed Omar", 2016, "LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial"], ["Janice Pogue", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Christopher M Reid", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Alexander Parkhomenko", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["John Varigos", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Robert McKelvie", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Katalin Keltai", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Dora I Molina", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Joanne Wilkinson", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Leopoldo S Piegas", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Irina Chazova", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Jun Zhu", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Khalid Yusoff", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Gilles Dagenais", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Ron JG Peters", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Lisheng Liu", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Eva M Lonn", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Karen Sliwa", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Patricio L\u00f3pez-Jaramillo", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Antonio Dans", 2016, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease"], ["Jose L Accini", 2016, "Blood-pressure and cholesterol lowering in persons without cardiovascular disease"], ["Peggy Gao", 2016, "Cholesterol lowering in intermediate-risk persons without cardiovascular disease"], ["Gregorio Sanchez-Vallejo", 2016, "Cholesterol lowering in intermediate-risk persons without cardiovascular disease"], ["John Xie", 2016, "Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks"], ["Kaj Stenl\u00f6f", 2016, "Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks"], ["Albert Fung", 2016, "Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks"], ["Gary Meininger", 2016, "Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks"], ["George Fodor", 2016, "Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of \u2026"], ["Robert J Petrella", 2016, "Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of \u2026"], ["Pierre Larochelle", 2016, "Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of \u2026"], ["Marcel Lebel", 2016, "Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of \u2026"], ["CHEP Guidelines Task Force", 2016, "Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of \u2026"], ["Richard I Ogilvie", 2016, "Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of \u2026"], ["Adam M Bernstein", 2016, "Effects of dietary pulse consumption on body weight: a systematic review and meta-analysis of randomized controlled trials"], ["Shana J Kim", 2016, "Effects of dietary pulse consumption on body weight: a systematic review and meta-analysis of randomized controlled trials"], ["Penny M Kris-Etherton", 2016, "Effects of dietary pulse consumption on body weight: a systematic review and meta-analysis of randomized controlled trials"], ["Benjamin Scirica", 2016, "CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL"], ["Eugene Braunwald", 2016, "CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL"], ["Ravi Patel", 2016, "CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL"], ["Ilaria Cavallari", 2016, "CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL"], ["Deepak Bhatt", 2016, "CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL"], ["Kyungah Im", 2016, "CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL"], ["Philippe Steg", 2016, "CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL"], ["Paul B Pencharz", 2016, "Effect of Dietary Pulses in a Low Glycemic Index Diet on Renal Function in Participants with Type 2 Diabetes Mellitus"], ["Vladimir VV Vuksan", 2016, "Effect of Dietary Pulses in a Low Glycemic Index Diet on Renal Function in Participants with Type 2 Diabetes Mellitus"], ["Edward Vidgen", 2016, "Effect of Dietary Pulses in a Low Glycemic Index Diet on Renal Function in Participants with Type 2 Diabetes Mellitus"], ["Anne Caroline dos Santos Dantas", 2016, "Acaricidal activity of Amburana cearensis on the cattle tick Rhipicephalus (Boophilus) microplus"], ["Jackson Roberto Guedes da Silva Almeida", 2016, "Acaricidal activity of Amburana cearensis on the cattle tick Rhipicephalus (Boophilus) microplus"], ["Alexsandro Branco", 2016, "Acaricidal activity of Amburana cearensis on the cattle tick Rhipicephalus (Boophilus) microplus"], ["Andreina de Carvalho Araujo", 2016, "Acaricidal activity of Amburana cearensis on the cattle tick Rhipicephalus (Boophilus) microplus"], ["Alessandra Gomes Marques Pacheco", 2016, "Acaricidal activity of Amburana cearensis on the cattle tick Rhipicephalus (Boophilus) microplus"], ["Luis Ant\u00f4nio Sangioni", 2016, "Acaricidal activity of Amburana cearensis on the cattle tick Rhipicephalus (Boophilus) microplus"], ["Mauricio Claudio Horta", 2016, "Acaricidal activity of Amburana cearensis on the cattle tick Rhipicephalus (Boophilus) microplus"], ["Alexandr Parkhomenko", 2016, "Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics"], ["Kamlesh Kunti", 2016, "Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics"], ["George J Fodor", 2016, "Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics"], ["Jae-Hyung Kim", 2016, "Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics"], ["HOPE-3 Investigators", 2016, "Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics"], ["Basil Lewis", 2016, "Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics"], ["Boaz Hirshberg", 2016, "Cardiovascular outcomes of patients in SAVOR-TIMI 53 by baseline hemoglobin A1c"], ["Jaime Davidson", 2016, "Cardiovascular outcomes of patients in SAVOR-TIMI 53 by baseline hemoglobin A1c"], ["Ph Gabriel Steg", 2016, "Cardiovascular outcomes of patients in SAVOR-TIMI 53 by baseline hemoglobin A1c"], ["Matthew A Cavender", 2016, "Cardiovascular outcomes of patients in SAVOR-TIMI 53 by baseline hemoglobin A1c"], ["S Sha", 2016, "Effect of canagliflozin on liver function tests in patients with type 2 diabetes"], ["T Forst", 2016, "Effect of canagliflozin on liver function tests in patients with type 2 diabetes"], ["DA Balis", 2016, "Effect of canagliflozin on liver function tests in patients with type 2 diabetes"], ["J Xie", 2016, "Effect of canagliflozin on liver function tests in patients with type 2 diabetes"], ["D Polidori", 2016, "Effect of canagliflozin on liver function tests in patients with type 2 diabetes"], ["JBL Hoekstra", 2016, "Frequency of cancer events with saxagliptin in the SAVOR\u2010TIMI 53 trial"], ["SAVOR\u2010TIMI 53 Steering Committee and Investigators", 2016, "Frequency of cancer events with saxagliptin in the SAVOR\u2010TIMI 53 trial"], ["CAM Stahre", 2016, "Frequency of cancer events with saxagliptin in the SAVOR\u2010TIMI 53 trial"], ["M Alvarsson", 2016, "Frequency of cancer events with saxagliptin in the SAVOR\u2010TIMI 53 trial"], ["BM Scirica", 2016, "Frequency of cancer events with saxagliptin in the SAVOR\u2010TIMI 53 trial"], ["Natalya P Trubitsyna", 2016, "Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation"], ["Milivoj Pileti\u010d", 2016, "Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation"], ["Latha Palaniappan", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["SS Chugh", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["M K\u00e4h\u00f6nen", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["David J Magid", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["ER Dorsey", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Heather J Fullerton", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["ES Ford", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Tanya N Turan", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["M Juonala", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["KJ Greenlund", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Robert W Yeh", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["DC Des Jarlais", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["OT Raitakari", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["DT Felson", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Emile R Mohler III", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["D Dicker", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Paul D Sorlie", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Amytis Towfighi", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Claudia S Moy", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["EL Ding", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Rachel H Mackey", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["N Hutri-K\u00e4h\u00f6nen", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["LT Cooper", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["M Alvarado", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["H Duber", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Daniel Woo", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Jean-Pierre Despr\u00e9s", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["RP Dellavalle", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["I Bolliger", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["MK Ali", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["RE Engell", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["G Danaei", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Melanie B Turner", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Alan S Go", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Wayne Rosamond", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Dariush Mozaffarian", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Donna K Arnett", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["M Ezzati", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["KE Colson", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Lynda D Lisabeth", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["E Carnahan", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["D Chou", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["W Couser", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Graham Nichol", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["MH Criqui", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["A Cohen", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Sarah de Ferranti", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["R Burstein", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["J Abraham", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Joel Stein", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["EJ Benjamin", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["H Chen", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["DH Bartels", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["V Mikkil\u00e4", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Mark D Huffman", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["KC Dabhadkar", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Robert W Neumar", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Virginia J Howard", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["N Dahodwala", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["BE Ebel", 2016, "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association."], ["Robert Mckelvie", 2016, "Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease"], ["D Phil", 2016, "Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease"], ["SUSTAIN-6 Investigators", 2016, "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes"], ["TS Campbell", 2016, "CHEP Guidelines Task Force"], ["J Kaczorowski", 2016, "CHEP Guidelines Task Force"], ["MD Hill", 2016, "CHEP Guidelines Task Force"], ["M Gelfer", 2016, "CHEP Guidelines Task Force"], ["M Vall\u00e9e", 2016, "CHEP Guidelines Task Force"], ["RA Hegele", 2016, "CHEP Guidelines Task Force"], ["KD Burns", 2016, "CHEP Guidelines Task Force"], ["L Trudeau", 2016, "CHEP Guidelines Task Force"], ["A Fournier", 2016, "CHEP Guidelines Task Force"], ["JC Gr\u00e9goire", 2016, "CHEP Guidelines Task Force"], ["RS Padwal", 2016, "CHEP Guidelines Task Force"], ["RJ Herman", 2016, "CHEP Guidelines Task Force"], ["G Moullec", 2016, "CHEP Guidelines Task Force"], ["RI Ogilvie", 2016, "CHEP Guidelines Task Force"], ["KL Lavoie", 2016, "CHEP Guidelines Task Force"], ["D Drouin", 2016, "CHEP Guidelines Task Force"], ["J Feber", 2016, "CHEP Guidelines Task Force"], ["SW Rabkin", 2016, "CHEP Guidelines Task Force"], ["M Khara", 2016, "CHEP Guidelines Task Force"], ["J Dionne", 2016, "CHEP Guidelines Task Force"], ["S Hiremath", 2016, "CHEP Guidelines Task Force"], ["K McBrien", 2016, "CHEP Guidelines Task Force"], ["LA Magee", 2016, "CHEP Guidelines Task Force"], ["RJ Petrella", 2016, "CHEP Guidelines Task Force"], ["P Lindsay", 2016, "CHEP Guidelines Task Force"], ["EL Schiffrin", 2016, "CHEP Guidelines Task Force"], ["NR Campbell", 2016, "CHEP Guidelines Task Force"], ["JM Boulanger", 2016, "CHEP Guidelines Task Force"], ["M Lebel", 2016, "CHEP Guidelines Task Force"], ["AG Logan", 2016, "CHEP Guidelines Task Force"], ["TW Wilson", 2016, "CHEP Guidelines Task Force"], ["G Fodor", 2016, "CHEP Guidelines Task Force"], ["KB Zarnke", 2016, "CHEP Guidelines Task Force"], ["G Benoit", 2016, "CHEP Guidelines Task Force"], ["RD Feldman", 2016, "CHEP Guidelines Task Force"], ["SA Lear", 2016, "CHEP Guidelines Task Force"], ["A Milot", 2016, "CHEP Guidelines Task Force"], ["SB Coutts", 2016, "CHEP Guidelines Task Force"], ["P Bolli", 2016, "CHEP Guidelines Task Force"], ["SW Tobe", 2016, "CHEP Guidelines Task Force"], ["M Lamarre-Cliche", 2016, "CHEP Guidelines Task Force"], ["JG Howlett", 2016, "CHEP Guidelines Task Force"], ["GW Moe", 2016, "CHEP Guidelines Task Force"], ["C Jones", 2016, "CHEP Guidelines Task Force"], ["V Woo", 2016, "CHEP Guidelines Task Force"], ["PA McFarlane", 2016, "CHEP Guidelines Task Force"], ["DM Rabi", 2016, "CHEP Guidelines Task Force"], ["K Nerenberg", 2016, "CHEP Guidelines Task Force"], ["RE Gilbert", 2016, "CHEP Guidelines Task Force"], ["A Pipe", 2016, "CHEP Guidelines Task Force"], ["G Tremblay", 2016, "CHEP Guidelines Task Force"], ["G Gubitz", 2016, "CHEP Guidelines Task Force"], ["L Poirier", 2016, "CHEP Guidelines Task Force"], ["P Hamet", 2016, "CHEP Guidelines Task Force"], ["A Prebtani", 2016, "CHEP Guidelines Task Force"], ["P Larochelle", 2016, "CHEP Guidelines Task Force"], ["M Sharma", 2016, "CHEP Guidelines Task Force"], ["E Burgess", 2016, "CHEP Guidelines Task Force"], ["R Lewanczuk", 2016, "CHEP Guidelines Task Force"], ["KC Harris", 2016, "CHEP Guidelines Task Force"], ["M Gupta", 2016, "CHEP Guidelines Task Force"], ["AA Leung", 2016, "CHEP Guidelines Task Force"], ["SL Bacon", 2016, "CHEP Guidelines Task Force"], ["K Dasgupta", 2016, "CHEP Guidelines Task Force"], ["P Selby", 2016, "CHEP Guidelines Task Force"], ["D Reid", 2016, "CHEP Guidelines Task Force"], ["L Cloutier", 2016, "CHEP Guidelines Task Force"], ["D McLean", 2016, "CHEP Guidelines Task Force"], ["SB Penner", 2016, "CHEP Guidelines Task Force"], ["M Ruzicka", 2016, "CHEP Guidelines Task Force"], ["P Oh", 2016, "CHEP Guidelines Task Force"], ["GK Dresser", 2016, "CHEP Guidelines Task Force"], ["S Grover", 2016, "CHEP Guidelines Task Force"], ["G Honos", 2016, "CHEP Guidelines Task Force"], ["SS Daskalopoulou", 2016, "CHEP Guidelines Task Force"], ["GV Prasad", 2016, "CHEP Guidelines Task Force"], ["MJ Blaha", 2016, "de FS, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER \u2026"], ["SR Das", 2016, "de FS, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER \u2026"], ["AS Go", 2016, "de FS, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER \u2026"], ["M Atanassova", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["Thitiworada Ittisan", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["R Balaji", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["EK Septiana", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["HKI Perera", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["F Ribarova", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["American Diabetes Association", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["K Tadera", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["S Hussain", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["M Al-Amin", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["A Mishra", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["JG Luo", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["T Thirumalai", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["R Sivakanesan", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["J Poongunran", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["B Liu", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["IS Yaddehige", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["MP Riya", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["AO Ademiluyi", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["T Henle", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["H Tang", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["A Mun'im", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["Benjamart Cushnie", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["LA Khan", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["SR Joshi", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["L Jayasinghe", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["PJ Houghton", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["Achida Jaruchotikamol", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["A Soumyanath", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["C Abeysena", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["J Xiao", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["EK Elumalai", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["E Attard", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["T Vidanapathirana", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["O Prakash", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["Pawitra Pulbutr", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["MS Islam", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["MS Nair", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["T Roy", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["F Gao", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["LY Kong", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["A Khan", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["JS Kim", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["R Rahman", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["Natcha Saweeram", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["TM Kalyankar", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["J Purintrapiban", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["D Marinova", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["S Sreedevi", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["V Kumar", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["HV Girish", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["E Yuan", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["N Lall", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["R Rathod", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["V Desseaux", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["JAJ Khan", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["R Mata", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["Nolte Kennedy", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["R Bye", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["MI Kazeem", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["A Bangun", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["V Sneha", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["A Ceriello", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["F Shan", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["A Rizwan", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["SM Saad", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["KH Son", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["S Kalra", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["T Matsuoka", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["G Bantwal", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["C Zhao", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["P Shah", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["J Yang", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["E David", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["KA Antu", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["SS Pekamwar", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["G Oboh", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["L Chen", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["G Marchis-Mouren", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["Y Minami", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["A Zamaludien", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["R Kuriyan", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["J Wang", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["H Kashtoh", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["BA Shibib", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["N Nkobole", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["A Perez-Vasquez", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["JO Adamson", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["L Hong", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["E Standl", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["X Chen", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["P Wongsa", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["JA Saliu", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["X Ni", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["F Dou", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["Q Wei", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["IA Ogunwande", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["X Tian", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["AJ Akinyemi", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["N Tamilselvan", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["G Jayakumar", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["L Monnier", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["A Wen", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["M Santimone", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["E Linares", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["M Al Kazaz", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["L Flores-Bocanegra", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["KPB Piyumal", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["L Ma", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["SPS Rani", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["F Yang", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["E Prodanov", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["M Hanefeld", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["N Keawpradub", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["R Rajendran", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["B Elya", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["AV Kurpad", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["Hattaya Intrama", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["K Basah", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["CS Kwon", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["KS Anilkumar", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["CK Chandrakanth", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["DPN Nair", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["SS Kokate", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["S Ghosh", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["C Ashok", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["SK Swaroop", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["U Schwarzenbolz", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["M Torres-Piedra", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["M Xi", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["J Bian", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["H Ali", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["MAAK Munasinghe", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["MMN Uddin", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["G Kai", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["K Takamatsu", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["N Tong", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["MD Ajithabai", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["Q Li", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["WIT Fernando", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["SH Robercyril", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["J Chaiwarit", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["A Hussein", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["W Yuliastuti", 2016, "Role of the water extract from Coccinia indica stem on the stimulation of glucose transport in L8 myotubes."], ["K Srichaikul", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["CWC Kendall", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["B Lamarche", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["D Faulkner", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["V Ramprasath", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["A Mirrahimi", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["C Ireland", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["DJA Jenkins", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["RJ De Souza", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["JL Sievenpiper", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["R Josse", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["J Frohlich", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["C Pellini", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["P Galange", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["LS Augustin", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["B Bashyam", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["VH Jayalath", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["P Couture", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["SK Nishi", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["PJ Jones", 2015, "The effect of a dietary portfolio compared to a DASH-type diet on blood pressure"], ["Pamela M Katz", 2015, "The role of the kidney and SGLT2 inhibitors in type 2 diabetes"], ["Keith AA Fox", 2015, "Cardiovascular risk factors and in-hospital mortality in acute coronary syndromes: insights from the Canadian global registry of acute coronary events"], ["Graham C Wong", 2015, "Cardiovascular risk factors and in-hospital mortality in acute coronary syndromes: insights from the Canadian global registry of acute coronary events"], ["Jenny Y Wang", 2015, "Cardiovascular risk factors and in-hospital mortality in acute coronary syndromes: insights from the Canadian global registry of acute coronary events"], ["Thao Huynh", 2015, "Cardiovascular risk factors and in-hospital mortality in acute coronary syndromes: insights from the Canadian global registry of acute coronary events"], ["Frederick A Spencer", 2015, "Cardiovascular risk factors and in-hospital mortality in acute coronary syndromes: insights from the Canadian global registry of acute coronary events"], ["Robert C Welsh", 2015, "Cardiovascular risk factors and in-hospital mortality in acute coronary syndromes: insights from the Canadian global registry of acute coronary events"], ["Ilana Saltzman", 2015, "Cardiovascular risk factors and in-hospital mortality in acute coronary syndromes: insights from the Canadian global registry of acute coronary events"], ["Jean-Pierre Dery", 2015, "Cardiovascular risk factors and in-hospital mortality in acute coronary syndromes: insights from the Canadian global registry of acute coronary events"], ["Alena Praneet Ng", 2015, "Effect of replacing animal protein with plant protein on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled trials"], ["Anthony J Hanley", 2015, "Effect of replacing animal protein with plant protein on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled trials"], ["Richard P Bazinet", 2015, "Effect of replacing animal protein with plant protein on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled trials"], ["Damir Boras", 2015, "Dosing irregularities and self-treated hypoglycemia in type 2 diabetes: results from the Canadian cohort of an international survey of patients and healthcare professionals"], ["Vincent C Woo", 2015, "Dosing irregularities and self-treated hypoglycemia in type 2 diabetes: results from the Canadian cohort of an international survey of patients and healthcare professionals"], ["T Ransom", 2015, "BLOOD PRESSURE MANAGEMENT IN PATIENTS WITH DIABETES: INSIGHTS FROM THE DIABETES MELLITUS STATUS IN CANADA (DM-SCAN) SURVEY"], ["MK Tan", 2015, "BLOOD PRESSURE MANAGEMENT IN PATIENTS WITH DIABETES: INSIGHTS FROM THE DIABETES MELLITUS STATUS IN CANADA (DM-SCAN) SURVEY"], ["AY Cheng", 2015, "BLOOD PRESSURE MANAGEMENT IN PATIENTS WITH DIABETES: INSIGHTS FROM THE DIABETES MELLITUS STATUS IN CANADA (DM-SCAN) SURVEY"], ["K Connelly", 2015, "BLOOD PRESSURE MANAGEMENT IN PATIENTS WITH DIABETES: INSIGHTS FROM THE DIABETES MELLITUS STATUS IN CANADA (DM-SCAN) SURVEY"], ["AT Yan", 2015, "BLOOD PRESSURE MANAGEMENT IN PATIENTS WITH DIABETES: INSIGHTS FROM THE DIABETES MELLITUS STATUS IN CANADA (DM-SCAN) SURVEY"], ["Sonia Blanco-Mejia", 2015, "Sugar-sweetened beverage consumption and incident hypertension: a systematic review and meta-analysis of prospective cohorts"], ["Arne Astrup", 2015, "Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice"], ["Rob C Andrews", 2015, "Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice"], ["N Finer", 2015, "Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice"], ["A Cuevas", 2015, "Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice"], ["M Kune\u0161ov\u00e1", 2015, "Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice"], ["DB Horn", 2015, "Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice"], ["David D Wang", 2015, "Effect of fructose on established lipid targets: a systematic review and meta\u2010analysis of controlled feeding trials"], ["Matthew Yu", 2015, "Effect of fructose on established lipid targets: a systematic review and meta\u2010analysis of controlled feeding trials"], ["Amanda J Carleton", 2015, "Effect of fructose on established lipid targets: a systematic review and meta\u2010analysis of controlled feeding trials"], ["S Patel", 2015, "Safety and efficacy of linagliptin in patients with type 2 diabetes and coronary artery disease: analysis of pooled incident investigator-reported events from phase 3 trials"], ["A Bhandari", 2015, "Safety and efficacy of linagliptin in patients with type 2 diabetes and coronary artery disease: analysis of pooled incident investigator-reported events from phase 3 trials"], ["U Hehnke", 2015, "Safety and efficacy of linagliptin in patients with type 2 diabetes and coronary artery disease: analysis of pooled incident investigator-reported events from phase 3 trials"], ["M Lehrke", 2015, "Safety and efficacy of linagliptin in patients with type 2 diabetes and coronary artery disease: analysis of pooled incident investigator-reported events from phase 3 trials"], ["OE Johansen", 2015, "Safety and efficacy of linagliptin in patients with type 2 diabetes and coronary artery disease: analysis of pooled incident investigator-reported events from phase 3 trials"], ["H-J Woerle", 2015, "Safety and efficacy of linagliptin in patients with type 2 diabetes and coronary artery disease: analysis of pooled incident investigator-reported events from phase 3 trials"], ["S Thiemann", 2015, "Safety and efficacy of linagliptin in patients with type 2 diabetes and coronary artery disease: analysis of pooled incident investigator-reported events from phase 3 trials"], ["I Satman", 2015, "Implementing an optimised glucose-lowering strategy in daily medical practice with first-and second-line gliclazide MR 60 mg"], ["MV Shestakova", 2015, "Implementing an optimised glucose-lowering strategy in daily medical practice with first-and second-line gliclazide MR 60 mg"], ["NP Trubitsyna", 2015, "Implementing an optimised glucose-lowering strategy in daily medical practice with first-and second-line gliclazide MR 60 mg"], ["M Piletic", 2015, "Implementing an optimised glucose-lowering strategy in daily medical practice with first-and second-line gliclazide MR 60 mg"], ["Eva Johnsson", 2015, "22. Long-Term Safety and Efficacy of Dapagliflozin in Patients with T2DM and Cardiovascular Disease (106-OR)"], ["Jennifer Sugg", 2015, "22. Long-Term Safety and Efficacy of Dapagliflozin in Patients with T2DM and Cardiovascular Disease (106-OR)"], ["S Paranjape", 2015, "Achieving postprandial glucose control with lixisenatide improves glycaemic control in patients with type 2 diabetes mellitus on basal insulin"], ["R Berria", 2015, "Achieving postprandial glucose control with lixisenatide improves glycaemic control in patients with type 2 diabetes mellitus on basal insulin"], ["W Canovatchel", 2015, "Simultaneous reduction in both HbA (1c) and body weight with canagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes mellitus over 104 weeks"], ["G Langslet", 2015, "Simultaneous reduction in both HbA (1c) and body weight with canagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes mellitus over 104 weeks"], ["Umesh Chaudhari", 2015, "Efficacy and safety of alirocumab in individuals with diabetes: analyses from the ODYSSEY LONG TERM study"], ["Christelle Lorenzato", 2015, "Efficacy and safety of alirocumab in individuals with diabetes: analyses from the ODYSSEY LONG TERM study"], ["Tjerk WA de Bruin", 2015, "Dapagliflozin\u2019s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo \u2026"], ["Shamik J Parikh", 2015, "Dapagliflozin\u2019s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo \u2026"], ["Frank Lichert", 2015, "Typ-2-Diabetes\u2013Untersuchung zur Wirksamkeit und Sicherheit von Canagliflozin"], ["Sanjay Patel", 2015, "Safety and Efficacy of Linagliptin in Patients with Type 2 Diabetes (T2D) and Coronary Artery Disease (CAD): Analysis of Pooled Incident Investigator Reported Events from Phase \u2026"], ["Odd-Erik Johansen", 2015, "Safety and Efficacy of Linagliptin in Patients with Type 2 Diabetes (T2D) and Coronary Artery Disease (CAD): Analysis of Pooled Incident Investigator Reported Events from Phase \u2026"], ["Hans-Juergen Woerle", 2015, "Safety and Efficacy of Linagliptin in Patients with Type 2 Diabetes (T2D) and Coronary Artery Disease (CAD): Analysis of Pooled Incident Investigator Reported Events from Phase \u2026"], ["Christine AM Stahre", 2015, "Saxagliptin and Cancer in the SAVOR-TIMI 53 Trial"], ["Michael Alvarsson", 2015, "Saxagliptin and Cancer in the SAVOR-TIMI 53 Trial"], ["Joost BL Hoekstra", 2015, "Saxagliptin and Cancer in the SAVOR-TIMI 53 Trial"], ["KM Prasanna Kumar", 2015, "Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial"], ["Robert Frederich", 2015, "Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial"], ["Christina Stahre", 2015, "Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial"], ["Alena Smahelova", 2015, "Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial"], ["Francois Bonnici", 2015, "Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial"], ["Daniel Sullivan", 2015, "Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes"], ["David Polidori", 2015, "Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes"], ["Keith Usiskin", 2015, "Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes"], ["Sue Sha", 2015, "Changes in Liver Function Tests (LFTs) with Canagliflozin (CANA) vs. Sitagliptin (SITA) in Patients with Type 2 Diabetes Mellitus (T2DM) Are Related to Changes in A1c and Body \u2026"], ["Dainius Balis", 2015, "Changes in Liver Function Tests (LFTs) with Canagliflozin (CANA) vs. Sitagliptin (SITA) in Patients with Type 2 Diabetes Mellitus (T2DM) Are Related to Changes in A1c and Body \u2026"], ["Thomas Forst", 2015, "Changes in Liver Function Tests (LFTs) with Canagliflozin (CANA) vs. Sitagliptin (SITA) in Patients with Type 2 Diabetes Mellitus (T2DM) Are Related to Changes in A1c and Body \u2026"], ["I Gause-Nilsson", 2015, "Wirksamkeit und Vertr\u00e4glichkeit von Dapagliflozin \u00fcber 2 Jahre bei T2DM-Patienten mit kardiovaskul\u00e4rer Vorerkrankung"], ["E Johnsson", 2015, "Wirksamkeit und Vertr\u00e4glichkeit von Dapagliflozin \u00fcber 2 Jahre bei T2DM-Patienten mit kardiovaskul\u00e4rer Vorerkrankung"], ["TWA de Bruin", 2015, "Wirksamkeit und Vertr\u00e4glichkeit von Dapagliflozin \u00fcber 2 Jahre bei T2DM-Patienten mit kardiovaskul\u00e4rer Vorerkrankung"], ["J Sugg", 2015, "Wirksamkeit und Vertr\u00e4glichkeit von Dapagliflozin \u00fcber 2 Jahre bei T2DM-Patienten mit kardiovaskul\u00e4rer Vorerkrankung"], ["SJ Parikh", 2015, "Wirksamkeit und Vertr\u00e4glichkeit von Dapagliflozin \u00fcber 2 Jahre bei T2DM-Patienten mit kardiovaskul\u00e4rer Vorerkrankung"], ["S Pieperhoff", 2015, "Wirksamkeit und Vertr\u00e4glichkeit von Dapagliflozin \u00fcber 2 Jahre bei T2DM-Patienten mit kardiovaskul\u00e4rer Vorerkrankung"], ["Donald W McKay", 2015, "The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension"], ["Canadian Hypertension Education Program", 2015, "The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension"], ["Guy de Backer", 2015, "Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society consensus panel statement on assessment, aetiology and management"], ["Connie B Newman", 2015, "Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society consensus panel statement on assessment, aetiology and management"], ["Erik Stroes", 2015, "Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society consensus panel statement on assessment, aetiology and management"], ["Evan Stein", 2015, "Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society consensus panel statement on assessment, aetiology and management"], ["Francois Mach", 2015, "Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society consensus panel statement on assessment, aetiology and management"], ["Cyril Kendall", 2015, "Effect of a Low Glycemic Index Diet on Markers of Oxidative Damage in Type 2 Diabetes"], ["Erika Reiser", 2015, "Effect of a Low Glycemic Index Diet on Markers of Oxidative Damage in Type 2 Diabetes"], ["Stephanie Nishi", 2015, "Effect of a Low Glycemic Index Diet on Markers of Oxidative Damage in Type 2 Diabetes"], ["Korbua Srichaikul", 2015, "Effect of a Low Glycemic Index Diet on Markers of Oxidative Damage in Type 2 Diabetes"], ["John Sievenpiper", 2015, "Effect of a Low Glycemic Index Diet on Markers of Oxidative Damage in Type 2 Diabetes"], ["Livia Augustin", 2015, "Effect of a Low Glycemic Index Diet on Markers of Oxidative Damage in Type 2 Diabetes"], ["David Jenkins", 2015, "Effect of a Low Glycemic Index Diet on Markers of Oxidative Damage in Type 2 Diabetes"], ["Ping He", 2015, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial"], ["Jose C Nicolau", 2015, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial"], ["Amarachi A Umez-Eronini", 2015, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial"], ["Jacob A Udell", 2015, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial"], ["Jacqueline Yee", 2015, "Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus"], ["Cindy Tong", 2015, "Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus"], ["Sonia Cerdas", 2015, "Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus"], ["David J Jenkins", 2015, "The Effects of Dietary Pulse Consumption on Body Weight: A Systematic Review and Meta-analysis of Randomized Controlled Trials"], ["Marco di Buono", 2015, "The Effects of Dietary Pulse Consumption on Body Weight: A Systematic Review and Meta-analysis of Randomized Controlled Trials"], ["Cyril W Kendall", 2015, "The Effects of Dietary Pulse Consumption on Body Weight: A Systematic Review and Meta-analysis of Randomized Controlled Trials"], ["Adrian Cozma", 2015, "Tree Nuts Improve Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Dietary Trials"], ["Russell De Souza", 2015, "Tree Nuts Improve Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Dietary Trials"], ["Viranda Jayalath", 2015, "Tree Nuts Improve Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Dietary Trials"], ["A Philis-Tsimikas", 2015, "Treatment intensification with insulin degludec improves glycaemic control in patients with Type 2 diabetes treated with liraglutide and metformin: P122"], ["P Raskin", 2015, "Treatment intensification with insulin degludec improves glycaemic control in patients with Type 2 diabetes treated with liraglutide and metformin: P122"], ["V Aroda", 2015, "Treatment intensification with insulin degludec improves glycaemic control in patients with Type 2 diabetes treated with liraglutide and metformin: P122"], ["T Bailey", 2015, "Treatment intensification with insulin degludec improves glycaemic control in patients with Type 2 diabetes treated with liraglutide and metformin: P122"], ["Kun-Ho Yoon", 2015, "Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized \u2026"], ["Dawn Millington", 2015, "Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized \u2026"], ["Pablo Arias", 2015, "Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized \u2026"], ["Dainius A Balis", 2015, "Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized \u2026"], ["Frank Vercruysse", 2015, "Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized \u2026"], ["Brian W McCrindle", 2015, "Obesity\u2014it must not remain the neglected risk factor in cardiology"], ["Eddy Lang", 2015, "Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia"], ["Cristina Villa-Roel", 2015, "Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia"], ["Andrew Worster", 2015, "Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia"], ["Ian Stiell", 2015, "Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia"], ["Mira Singh", 2015, "Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia"], ["Marcia L Edmonds", 2015, "Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia"], ["Brian H Rowe", 2015, "Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia"], ["Marc Afilalo", 2015, "Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia"], ["Frank Scheuermeyer", 2015, "Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia"], ["Samuel Campbell", 2015, "Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia"], ["Jennifer Riley", 2015, "Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia"], ["Marco Sivilotti", 2015, "Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia"], ["Canadian Association of Emergency Physicians Research Consortium", 2015, "Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia"], ["Sarah De Ferranti", 2015, "Executive summary: heart disease and stroke statistics\u20142015 update: a report from the American Heart Association"], ["VJ Howard", 2015, "Mohler 3rd"], ["BM Kissela", 2015, "Mohler 3rd"], ["MD Huffman", 2015, "Mohler 3rd"], ["HJ Fullerton", 2015, "Mohler 3rd"], ["LD Lisabeth", 2015, "Mohler 3rd"], ["DB Matchar", 2015, "Mohler 3rd"], ["S De Ferranti", 2015, "Mohler 3rd"], ["JP Despres", 2015, "Mohler 3rd"], ["DT Lackland", 2015, "Mohler 3rd"]]}